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The difficulties involved in conditionally perturbing complex gene expres-
sion networks represent major challenges toward defining the mechanisms
controlling human development, physiology, and disease. We developed an
OPTimized inducible KnockDown (OPTiKD) platform that addresses the lim-
itations of previous approaches by allowing streamlined, tightly-controlled,
and potent loss-of-function experiments for both single and multiple genes.
The method relies on single-step genetic engineering of the AAVS1 genomic
safe harbor with an optimized tetracycline-responsive cassette driving one or
more inducible short hairpin RNAs (shRNAs). OPTiKD provides homoge-
neous, dose-responsive, and reversible gene knockdown. When implemented
in human pluripotent stem cells (hPSCs), the approach can be then applied
to a broad range of hPSC-derived mature cell lineages that include neurons,
cardiomyocytes, and hepatocytes. Generation of OPTiKD hPSCs in commonly
used culture conditions is simple (plasmid based), rapid (two weeks), and highly
efficient (>95%). Overall, this method facilitates the functional annotation of
the human genome in health and disease. C© 2018 by John Wiley & Sons, Inc.
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INTRODUCTION
Human pluripotent stem cells (hPSCs) represent an invaluable model to both understand
human development and generate a wide variety of cell types useful for disease modeling
and drug screening (Avior, Sagi, & Benvenisty, 2016; Pourquié, Bruneau, Keller, &
Smith, 2015; Trounson & DeWitt, 2016). However, functional analyses of complex
developmental and disease mechanisms using hPSCs require efficient ways to probe
gene function. Unfortunately, manipulation of gene expression in hPSCs is extremely
complex, as most traditional methods such as transfection and transduction are poorly
effective (Cao et al., 2010; Costa et al., 2007; Ellis, 2005; Herbst et al., 2012; Luo, Lü,
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Pan, & Long, 2016; Yao et al., 2004). Moreover, manipulation of gene expression is
complicated by the need for maintaining such cells in a self-renewing undifferentiated
state (thus complicating the study of genes regulating pluripotency), and by the difficulty
in determining the stage-specific role of genes involved at multiple steps during lineage
specification. Overall, stable loss- or gain-of-function experiments in hPSCs have only
limited value, while conditional manipulation of gene expression is crucial to fully
harness the power of hPSCs for functional genetics applications.
Inducible gene knockdown using short hairpin RNAs (shRNAs) is an established method
to study gene function in many cell types (Boettcher & McManus, 2015; Lambeth &
Smith, 2013). In this context, the tetracycline-derepressible (TET-OFF) system is the
most widely used approach (Kappel, Matthess, Kaufmann, & Strebhardt, 2007; Lambeth
& Smith, 2013). This relies on a modified RNA polymerase III (Pol III) promoter
that is responsive to a tetracycline-sensitive Repressor protein (tetR). Following simple
tetracycline treatment, the tetracycline-bound tetR undergoes a conformational change
that prevents its binding to the Pol III promoter, which is therefore derepressed. As a
result, the shRNA is induced and drives gene knockdown. However, application of the
TET-OFF system in hPSCs has proven challenging for two main reasons: (1) tight control
of shRNA expression is difficult to achieve; (2) induction of the shRNA rarely works
in differentiated derivatives. Indeed, very high and homogenous expression of both the
tetR and the inducible shRNA is required to obtain a potent yet controlled knockdown.
However, standard methods rely either on lentiviruses or on randomly integrated plasmids
(Laperle et al., 2015; Lian et al., 2012; Massé et al., 2011; Tsuneyoshi et al., 2012;
Zafarana, Avery, Avery, Moore, & Andrews, 2009), which are plagued by heterogeneous
expression and transgene silencing in hPSCs, in particular when such transgenes are
located in regions where heterochromatin forms following cell fate choices (Herbst et al.,
2012; Raya et al., 2009).
We recently developed an alternative approach to implement optimized inducible shRNA
expression in hPSCs (Figure 5C.4.1A; Bertero et al., 2016). This method takes advantage
of recent advances in gene editing based on programmable nucleases to induce controlled
transgenesis into human genomic safe harbors (GSHs), regions in the human genome that
are expressed in virtually any human cell type, are resistant to gene silencing, and can be
genetically modified without negatively affecting cellular functionality (Gaj, Gersbach,
& Barbas, 2013; Hockemeyer et al., 2009; Pawlowski et al., 2017; Sadelain, Papapetrou,
& Bushman, 2012; Smith et al., 2008). We developed an all-in-one targeting approach
to deliver a TET-OFF-inducible shRNA expression cassette to the AAVS1 GSH, and
combined this method with an optimized tetR protein that virtually eliminates premature
shRNA expression in the absence of tetracycline. This technology, which we named
OPTiKD for OPTimized inducible KnockDown, allows streamlined generation of hPSCs
in which expression of individual or multiple genes can be conditionally manipulated in a
homogeneous, rapid, dose-responsive, and reversible fashion (Figure 5C.4.1B). Further,
we demonstrated that this approach is fully functional even after differentiation of hPSCs
into a panel of more than twelve hPSC-derived lineages, including cell types of major
clinical interest such as neurons, cardiomyocytes, and hepatocytes (Bertero et al., 2016).
This unit describes all the steps involved in generating and validating OPTiKD hPSCs.
The main method is subdivided into four basic protocols to be followed in chronological
order (Figure 5C.4.2):
 Basic Protocol 1: Design of oligonucleotides for shRNA cloning
 Basic Protocol 2: Generation of inducible shRNA targeting vectors
 Basic Protocol 3: Generation of OPTiKD hPSCs
































































Figure 5C.4.1 The optimized inducible knockdown (OPTiKD) system. (A) Schematic of the generation of
OPTiKD human pluripotent stem cells (hPSCs) and of the resulting genetic circuit which allows tetracycline
(TET)–dependent induction of gene knockdown both in hPSCs and hPSC-derived cells. i-shRNA: inducible
short hairpin RNA. (B) Schematic of the properties of OPTiKD (refer to Figure 5C.4.7 for example of expected











































Basic Protocol 1 
shRNA design (1 day)
Basic Protocol 2 or Alternate Protocol 1
Cloning of shRNA vector (3-5 days)
Support Protocol 1




AAVS1 gene targeting (7-14 days)
Basic Protocol 4
Validation (7 days onwards)
+/- TET
+/- TET
Figure 5C.4.2 Generation and characterization of OPTiKD hPSCs. Schematic overview of the procedure detailing how
the various protocols relate to each other. Optional steps are indicated by dashed arrows. PuroR: puromycin resistance;
H1: H1 Pol III promoter; TO: tet operator; ZFN: zinc-finger nucleases. Refer to the text for other common abbreviations.
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In addition to this, the Alternate Protocol provides a method for medium-throughput
generation of several shRNA targeting vectors in parallel. Finally, two support protocols
describe optional steps for the generation of OPTiKD targeting vectors expressing mul-
tiple inducible shRNAs (Support Protocol 1) and for the clonal isolation and genotyping
of OPTiKD hPSCs (Support Protocol 2). The whole procedure can be completed in
3 to 9 weeks, depending on the experimental design and expertise of the investigator, and
allows generation of OPTiKD hPSCs with >95% efficiency.
BASIC
PROTOCOL 1
DESIGN OF OLIGONUCLEOTIDES FOR shRNA CLONING
The first step in generating OPTiKD hPSCs consists in obtaining oligonucleotides to
be used to clone the shRNA sequence in the targeting vector. First, a suitable shRNA
sequence must be identified. Second, oligonucleotides are designed to add appropriate
5′- and 3′-end overhangs to facilitate directional cloning.
1.A: shRNA design
Identifying a good shRNA is the most critical parameter when generating OPTiKD
hPSCs (see Commentary). Validated shRNA sequences can be obtained from various
sources such as previous reports in the scientific literature, public shRNA databases,
or commercial suppliers. Alternatively, shRNAs can be designed in house by using
available algorithms (reviewed in Fakhr, Zare, & Teimoori-Toolabi, 2016). For genes
that have no reported validated shRNA, we advise investigators to take advantage
of the RNAi Consortium shRNA library (also known as the TRC library or the Ge-
netic Perturbation Platform: https://portals.broadinstitute.org/gpp/public/; Moffat et al.,
2006), which contains pre-designed shRNAs for all human genes, >50% of which
have been experimentally validated. Such validation data is available from Sigma-
Aldrich, one of the commercial distributors of the TRC library (https://www.sigmaaldrich
.com/life-science/functional-genomics-and-rnai/shrna/individual-genes.html).
This basic protocol assumes that an shRNA from the TRC library is being used.
When using alternative sources for an shRNA, ignore steps 1, 2, and 3 of this pro-
tocol and proceed directly to step 4. The OPTiKD method has been successfully
used with a variety of shRNA designs (Bertero et al., 2016). When designing the
shRNA in house, make sure to follow appropriate design rules according to the most
recent literature on the topic (reviewed in Fakhr et al., 2016). Further, it is cru-
cial to avoid shRNAs containing a poly(T) tract longer than four nucleotides, as this
could lead to premature shRNA termination (TRC library shRNA are pre-screened
to avoid this problem). We generated an electronic worksheet file that can be used
to perform all the oligonucleotide design steps (steps 4 to 6) in an automatic fash-
ion; we recommend using such tool once familiar with the design principles described
here. The worksheet can be downloaded from https://docs.google.com/spreadsheets/d/
18jzVw-5kHzw8xAXkvvFYZizL-y5Hapb1r4Fp6zTXk4U/edit?usp=sharing.
1.B: Design of oligonucleotides for cloning the shRNA into the targeting vector
The cloning procedure will be described in more detail in Basic Protocol 2. Briefly,
two single-stranded oligonucleotides are annealed to form a double-stranded DNA se-
quence containing the shRNA sequence followed by a Pol III terminator (consisting
of a stretch of four or more thymidines), as well as 5′- and 3′-end “sticky” overhangs
that are complementary to those generated in the targeting vector following restriction
digestion with BglII and SalI (Figure 5C.4.3E and Figure 5C.4.4C). This design fa-
cilitates directional cloning of the shRNA into the targeting vector. Furthermore, the
oligonucleotides are designed to destroy the BglII restriction enzyme site in the final
plasmid in order to allow screening of correct recombinant clones by diagnostic restric-
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Figure 5C.4.3 Design of shRNAs for OPTiKD. Example of the design procedure described in
Basic Protocol 1. The relevant sequence elements are color-coded. +1 G/A: guanine/adenosine
found on the first translated nucleotide following cloning into the H1 promoter. (A) Sequence from
the TRC shRNA database as obtained from the Sigma-Aldrich Web site (top) and after trimming of
extra nucleotides (shRNA proper, bottom). (B) shRNA modified to start with a guanine to ensure
maximal activity of the H1 promoter. The predicted hairpin secondary structure is shown on the
bottom. (C) Top oligonucleotide for shRNA cloning. (D) Reverse complement of the shRNA in panel
B (top), and bottom oligonucleotide for shRNA cloning (bottom). (E) Predicted double-stranded
DNA obtained after annealing of the top and bottom oligonucleotides from panels C and D.
efficient and precise when a guanine (“G”) or an adenosine (“A”) base is found on the
+1 site (Ma et al., 2014; Ranganathan, Wahlin, Maruotti, & Zack, 2014), the shRNA is
modified to satisfy this criteria if needed.
Materials
SnapGene software (GSL Biotech LLC)
1. Obtain a shRNA target sequence for the gene of interest from the TRC library
(https://portals.broadinstitute.org/gpp/public/gene/search).
Search the gene of interest by its official gene symbol: a list of all available shRNAs will
appear and can be visualized online or downloaded as a comma-separated (CSV) file. In
this list, identify the 20- to 21-bp-long target sequence (sense shRNA target site).
2. Check that the 21-bp sense shRNA target site maps to the desired transcript by using
BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi).
A 100% match is to be expected. The shRNAs from the TRC library have been designed
to target all annotated isoforms of a given gene, but as annotations are ever evolving it is
possible that the isoform of interest might not be targeted by the selected shRNA. If so go
back to step 1 and select a new shRNA.
3. Design the shRNA sequence by joining the following segments in 5′ to 3′ orientation:
a. The sense shRNA target site identified in step 1.
b. The 6-bp “loop” sequence 5′-CTCGAG-3′.
c. The reverse complement of the sense shRNA target site identified in step 1 (anti-
sense shRNA target site).
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Note that the shRNAs listed on the Sigma-Aldrich Web site will most likely have initial
“CCGG” and final “TTTTTG/TTTTG” sequences, which must be ignored as these are
not part of the shRNA proper. When the shRNA sequence is transcribed by Pol III, it will
form a hairpin structure with the complementary sense and antisense target sites forming
a stem through Watson-Crick base pair interactions, and an extruding 6-bp loop (Figure
5C.4.3B).
4. Check to see if the sense shRNA target site starts with a guanine (“G”) or an adeno-
sine (“A”): if not, insert a “G” at the beginning of the sense shRNA target site
(Figure 5C.4.3B).
Note that a complementary final “C” should not be added to the antisense shRNA target
site, as the extra “G” hanging on the 5-end of the shRNA will not create any issue and it
is better to preserve the structure of the 20- to 21-bp-long hairpin.
5. Design the “top” oligonucleotide by:
a. Taking the shRNA sequence from step 4.
b. Adding 5′-GATCCC-3′ to the 5′-end.
c. Adding 5′-TTTTTTG-3′ to the 3′-end (Figure 5C.4.3C).
6. Design the “bottom” oligonucleotide by:
a. Obtaining the reverse complement of the shRNA sequence from step 4.
b. Adding 5′-TCGACAAAAAA-3′ to the 5′-end.
c. Adding 5′-GG-3′ to the 3′ end (Figure 5C.4.3D).
The additions from this and the previous step contribute to creating the appropriate
overhangs for subsequent directional cloning and the Pol III terminator sequence.
7. Optional: Use SnapGene software for in silico simulation of the subsequent cloning
step by:
a. Annealing the oligonucleotides.
b. Digesting pAAV-Puro_siKD with BglII and SalI (for the sequence see Materials
in Basic Protocol 2).
c. Ligating the two fragments.
Save the resulting plasmid map for later use.
We strongly recommend this step to verify that the oligonucleotides are predicted to anneal
perfectly and form a structure with the overhangs required for the subsequent cloning step
(Figure 5C.4.3E). Furthermore, the resulting plasmid map will be used to facilitate the
ensuing analysis of sequencing results of plasmid clones. If SnapGene is unavailable, use
equivalent software for in silico analysis of DNA sequences and simulation of molecular
cloning procedures.
8. Order top and bottom oligonucleotides as desalted purified products from Sigma-
Aldrich or from an alternative preferred commercial supplier.
A production scale of 0.05 µmol is sufficient. PAGE purification of the oligonucleotides




GENERATION OF INDUCIBLE shRNA TARGETING VECTOR
In this second part of the procedure, the oligonucleotides obtained from Basic Protocol 1
are used to generate an AAVS1 targeting vector for inducible shRNA expression. First,
the oligonucleotides are annealed, phosphorylated, and ligated to a pre-digested plasmid.
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Figure 5C.4.4 Cloning of shRNAs into the OPTiKD plasmid. (A) Map of the plasmid used to generate OPTiKD hPSCs.
The position of restriction sites and primers relevant to the protocol is shown. HA-L/R: left/right homology arm; SA: splice
acceptor; T2A: self-splicing T2A sequence; PuroR: puromycin resistance cDNA; pA: polyadenylation sequence; H1-TO:
tetracycline-inducible H1 RNA Polymerase III promoter containing a tet operator; CAG: CMV early enhancer, chicken
β-actin and rabbit β-globin hybrid promoter; OPTtetR: codon-optimized tetracycline-responsive repressor protein cDNA;
ccdB: ccdB toxin (truncated and thus inactive); KanR: kanamycin resistance; AmpR: ampicillin resistance; ori: high-copy
origin of replication. (B) Nucleotide sequence of the tetracycline-inducible H1-TO RNA Polymerase III promoter. Key
sequence features are color coded, and the locations of primers are show with arrows indicating their 5′-3′ directionality.
The restriction enzyme cut sites used for shRNA cloning are shown in boxes. DSE: distal sequence element; PSE: proximal
sequence element; TETO2: tet operator; +1: start position of RNA transcription. (C) Schematics of the shRNA cloning
procedure described in Basic Protocol 2. The portion of the vector being cut is shown on top, and the restriction enzyme
sites and resulting overhangs are indicated. The +1 position is in yellow (panel B). The double-stranded oligonucleotide
containing the shRNA (Figure 5C.4.3E) is schematized in the middle. The product resulting from ligation of the cut vector
and insert is on the bottom. Note that the BglII site is destroyed after ligation. (D) Representative example of colony PCR
results from six screened bacterial clones. Clones with the expected larger amplification product are indicated. siKD:
control PCR performed on pAAV-Puro_siKD (indicating the size of the empty vector).
Finally, bacterial clones are screened to identify correct recombinants that will be used
for plasmid preparation and subsequent gene targeting.
2.A: The OPTiKD plasmid
This OPTiKD method is based on usage of pAAV-Puro_siKD (Figure 5C.4.4A), a
bacterial plasmid which allows selective gene targeting of an all-in-one tetracycline-
inducible shRNA cassette into the human AAVS1 locus (PPP1R12C gene, located on
chromosome 19). The gene targeting step is described in detail in Basic Protocol 3.
Briefly, this is achieved by the generation of a genomic DNA double-strand break by
obligate heterodimer zinc-finger nucleases (ZFN) that target the first intron of PPP1R12C
(Bertero et al., 2016; Hockemeyer et al., 2009). Such DNA damage is resolved via
homologous directed-repair (HDR) based on the presence of two homology arms on
pAAV-Puro_siKD that map to the 5′- and 3′-end of the double-strand break. This leads
to the insertion of the DNA cassette present between the 5′- and 3′-end homology arms.
This DNA cassette contains an antibiotic drug resistance gene trap that facilitates the
selection of gene targeted hPSCs, and is followed by the all-in-on-inducible shRNA
cassette proper.
The antibiotic drug resistance gene used is puromycin-N-acetyltransferase (PAT), which
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and specifically select eukaryotic cells. The PAT gene is driven by the endogenous
PPP1R12C promoter through a gene-trap approach rather than relying on an autonomous
promoter (Hockemeyer et al., 2009). This strategy relies on a strong splice acceptor that
“hijacks” the PPP1R12C transcripts and splices in the PAT cDNA. This design strongly
increases the probability that drug-resistant hPSCs are the result of correct gene targeting
to the AAVS1 locus. Indeed, random integration of the pAAV-Puro_siKD plasmid will
most often not result in expression of the PAT gene due to the lack of a dedicated promoter
(the exception to this is if the plasmid is integrated in an intronic region of an expressed
gene, but this is a rare event that in our experience occurs with less than 5% frequency;
see Basic Protocols 3 and 4). Note that random integration of the targeting plasmid is an
event that happens with comparable if not higher frequency to site-specific gene targeting
through HDR. Therefore, the use of a gene-trap approach for the drug resistance gene is
key to obtaining correctly targeted cells with high frequency (in our experience this is
more than 95%; see Basic Protocols 3 and 4).
The inducible shRNA is placed under the transcriptional control of an H1 Pol III promoter
modified to include a tet operator sequence (TO) after the TATA box (H1-TO promoter,
Figure 5C.4.4B; Brummelkamp, Bernards, & Agami, 2002). Under control conditions
(absence of the drug tetracycline) this promoter is efficiently bound by the tetR protein,
which prevents expression of the shRNA. The tetR protein is expressed from the same
targeting vector and is under the transcriptional control of the strong constitutive CAG
promoter, which is highly expressed and resistant to silencing in hPSCs and differentiated
cell types. The tetR protein was subjected to multi-parameter codon and RNA optimiza-
tion for expression in human cells (Fath et al., 2011), which increased its steady-state
expression by approximately one order of magnitude (Bertero et al., 2016). We named
the resulting product OPTtetR, for codon OPTimized tetR, and demonstrated that when
expressed in the all-in-one inducible shRNA OPTiKD cassette it was sufficient to virtu-
ally abolish “leaky” expression of the shRNA in the absence of tetracycline, a problem
which was shown to markedly plague traditional TET-OFF-inducible shRNA methods
based on the wild-type bacterial tetR (Bertero et al., 2016; Henriksen et al., 2007). We
also showed that the OPTtetR is fully derepressible by addition of tetracycline, thus
maximizing the dynamic range of inducible knockdown. The beneficial effects of using
the OPTtetR are most likely due to its higher protein expression, which is expected to
ensure higher binding efficiency to the cognate TO site and thus more consistent repres-
sion (Gray et al., 2007). Note that in contrast to the PAT gene the OPTtetR expression
is driven by a constitutive promoter independent from the integration site. This strategy
ensures stable expression even upon differentiation of hPSCs into lineages that might
show low transcriptional activity of the PPP1R12C gene. A final point of note is that
the orientation of the inducible shRNA and constitutive OPTtetR expression cassettes
is key to the functionality of the all-in-one approach described here (A. Bertero unpub.
observ.).
Transcription of the two Pol II-dependent transgenes (PAT and OPTtetR) is terminated by
the strong bovine growth hormone polyadenylation signal, while the shRNA is terminated
by a poly(T) tract (see Section 1.B in the introduction to Basic Protocol 1). The plasmid
backbone contains a pUC bacterial origin of replication for high-copy plasmid production
in E. coli, and an ampicillin resistance gene to allow selective propagation of bacteria
containing the recombinant plasmid (a kanamycin resistance gene is also present but not
used for the procedure described here). Note that a partial ccdB gene (which encodes
for a bacterial toxin that poisons DNA gyrase) is present on the backbone, but this is
not functional, as it lacks a start codon (this represents a remnant from the original
backbone used to generate pAAV-Puro_siKD). Therefore, usage of special E. coli strains
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2.B: Cloning of shRNA into the OPTiKD plasmid
The shRNA is cloned into pAAV-Puro_siKD by means of a simplified restriction
enzyme–based molecular cloning step. The plasmid is cut with two different restric-
tion enzymes (BglII and SalI), thus generating distinct and non-compatible sticky
5′- and 3′-end overhangs that allow directional cloning (Figure 5C.4.4C). As single- and
double-cut plasmids cannot be distinguished based on their size by traditional agarose
gel DNA electrophoresis, the digested plasmid is also dephosphorylated. This is done
to reduce the rate of self-ligation of contaminating molecules in which only one of the
two restriction sites was successfully digested (and that are thus presenting compatible
sticky ends). This means that the double-stranded DNA encoding for the shRNA obtained
from annealed oligonucleotides must be phosphorylated prior to ligation. As mentioned
in Section 1.B (see introduction to Basic Protocol 1), the BglII site is destroyed upon
successful ligation, which facilitates screening of recombinant plasmids by diagnostic
restriction digestion (Figure 5C.4.4C). Following successful ligation, the shRNA se-
quence will be placed so that the first base to be transcribed (a guanine or alanine; see
Section 1.B in the introduction to Basic Protocol 1) is on the +1 position (indicating
the known transcriptional start site of the H1 promoter, which is 26 bp downstream the
end of the TATA box; Figure 5C.4.4B). The poly(T) stretch after the shRNA sequence
functions as transcriptional terminator for Pol III. Recombinant plasmids isolated from
bacterial clones are screened by colony PCR and/or diagnostic restriction digestion, and
correct ligation products are further screened by Sanger sequencing to confirm that no
mutations are present in the shRNA sequence. The inducible shRNA plasmid is finally
expanded into E. coli in preparation to the gene targeting step (Basic Protocol 3).
Materials
pAAV-Puro_siKD plasmid [Addgene, cat. no. 86695; alternatively contact the
corresponding authors (abertero@uw.edu; lv225@cam.ac.uk)]
FastDigest BglII (ThermoFisher, cat. no. FD0083)
FastDigest SalI (ThermoFisher, cat. no. FD0644)
FastAP Thermosensitive Alkaline Phosphatase (1 U/µl; ThermoFisher, cat. no.
EF0654)
10× FastDigest Green Buffer (ThermoFisher, cat. no. B72)
Ultrapure DNase/RNase-free distilled water (ThermoFisher, cat. no. 10977015)
6× gel loading dye (New England Biolabs, cat. no. B7024S)
1% (w/v) agarose gel in TBE containing 0.5 μg/ml ethidium bromide (see recipe;
use molecular biology grade agarose; ThermoFisher, cat. no. 17850)
1 Kb plus DNA ladder (ThermoFisher, cat. no. 10787018)
QIAEX II Gel Extraction Kit (Qiagen, cat. no. 20021)
“Top” single-stranded oligonucleotide for shRNA (custom oligonucleotide; Basic
Protocol 1, step 8)
“Bottom” single-stranded oligonucleotide for shRNA (custom oligonucleotide;
Basic Protocol 1, step 8)
T4 DNA Ligase Reaction Buffer (New England Biolabs, cat. no. B0202S)
T4 Polynucleotide Kinase (New England Biolabs, cat. no. M0201S)
4% (w/v) agarose gel in TBE containing 0.5 μg/ml ethidium bromide (see recipe;
use UltraPure Low Melting Point Agarose; ThermoFisher, cat. no. 16520050)
Rapid DNA Ligation Kit (ThermoFisher, cat. no. K1422)
α-select Gold Efficiency E. coli (Bioline, cat. no. BIO-85027)
SOC medium (ThermoFisher, cat. no. 15544034)
LB agar plates containing 100 µg/ml ampicillin (see recipe)
siKD_fw primer (custom oligonucleotide, see Table 5C.4.1)
siKD_rev primer (custom oligonucleotide, see Table 5C.4.1)
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Table 5C.4.1 Oligonucleotides for Cloning Experiments
Primer name Sequence (5′ → 3′)
Generation of inducible shRNA targeting vector (Basic protocol 2)
siKD_fw CGAACGCTGACGTCATCAACC
siKD_rev GGGCTATGAACTAATGACCCCG























aThe 3′-most common portion of each forward primer is: 5′-CGAACGCTGACGTCATCAAC-3′. The 5′-most portion is specific to the desired overlap
to be created following PCR amplification (Table 5C.4.2).
bThe 3′-most common portion of each reverse primer is: 5′-GTAACGCGGAACTCCATATATGG-3′. The 5′-most portion is specific to the desired
overlap to be created following PCR amplification (Table 5C.4.2).
GoTaq Flexi DNA Polymerase (Promega, cat. no. M8291)
Luria Bertani (LB) broth containing 100 µg/ml ampicillin (see recipe)
1.5% (w/v) agarose gel in TBE containing 0.5 μg/ml ethidium bromide (see recipe;
use standard molecular biology grade agarose)
QIAprep Spin Miniprep Kit (Qiagen, cat. no. 27104)
Glycerol for molecular biology, >99% (Sigma-Aldrich, cat. no. G5516-100ML)
QIAfilter Plasmid Midi Kit (Qiagen, cat. no. 12243)
UV transilluminator
PCR tubes
Thermocycler with heated lid
Heated water bath
Humidified bacterial incubator
Sanger sequencing facility (or commercial provider)
Bacterial culture orbital shaker
Additional reagents and equipment for agarose gel electrophoresis (Voytas, 2001)
2.C: Preparation of cloning vector
1. One-step digest and dephosphorylate pAAV-Puro_siKD by preparing the following
reaction:
a. pAAV-Puro_siKD Variable volume (5 µg)
b. FastDigest BglII 3 µl
c. FastDigest SalI 3 µl
d. FastAP (1 U/µl) 3 µl
e. FastDigest Green Buffer (10×) 9 µl






Supplement 44 Current Protocols in Stem Cell Biology
Incubate for 1 hr at 37°C.
A shorter incubation of 5 to 30 min can alternatively be performed, as these enzymes
are fast cutters, but we recommend 1 hr to maximize efficiency since a large amount
of plasmid is being digested. No significant restriction enzyme star activity should be
observed for up to 3 hr of incubation, and a longer incubation time is not recommended.
The above reaction can be scaled down to digest 1 to 2 µg of plasmid if desired. However,
we find it is best to prepare a larger batch of plasmid to be used for multiple ligations.
2. Add 18 µl of gel loading dye, mix and run on a 1% (w/v) agarose gel in TBE
containing 0.5 μg/ml ethidium bromide. Include the DNA ladder in one separate
well as molecular weight control. Visualize the DNA using a UV transilluminator,
excise the 9466-bp band with a clean scalpel, and perform DNA gel extraction
using QIAEX II Gel Extraction Kit according to the manufacturer’s instructions and
aiming for a final concentration of 25 to 100 ng/µl.
Essential protocols for agarose gel electrophoresis are included in Voytas (2001).
It is advisable to run 500 ng of uncut plasmid in a separate well as control for com-
plete digestion. Should undigested plasmid be contaminating the preparation, we advise
repeating step 1 with a longer incubation time and/or reducing the amount of plasmid
being digested. When a large plasmid batch is being prepared, divide the gel-extracted
vector in 5- to 10-µl aliquots and store for later use at –20°C for at least 6 months.
Ethidium bromide is a known carcinogen and should be handled with care while wearing
appropriate personal protective equipment and in accordance with local safety regula-
tions. Alternative products carrying lower risk for carcinogenesis are available on the
market and are an advisable alternative wherever possible.
2.D: Preparation of shRNA inserts
3. Assemble the following reaction in a PCR tube:
a. Top oligo (200 µM in ddH2O) (Basic Protocol 1) 5 µl
b. Bottom oligo (200 µM in ddH2O) (Basic Protocol 1) 5 µl
c. T4 DNA Ligase Reaction Buffer (10×) 2 µl
d. T4 Polynucleotide Kinase 1 µl
e. Ultrapure ddH2O 7 µl
4. Phosphorylate, denature, and anneal the shRNA oligonucleotides by incubating the
reaction from step 3 in a thermocycler according to the following program (lid kept
at 95°C):
a. 37°C 1 hr
b. 95°C 5 min
Ramp down to 80°C at –0.1°C/sec:
c. 80°C 4 min
Ramp down to 75°C at –0.1°C/sec:
d. 75°C 4 min
Ramp down to 70°C at –0.1°C/sec:
e. 70°C 4 min
Ramp down to 10°C at –0.1°C/sec:
f. 10°C hold
The phosphorylated and annealed double-stranded oligonucleotides can be stored at
4°C for maximum of 24 hr or at –20°C for at least 2 weeks. This annealing protocol has
been optimized for shRNAs, as cooling from 95°C to 70°C is very slow, with extensive
pauses to facilitate annealing of oligonucleotides that have a high melting temperature
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5. Optional: Verify the annealing by running 10 pmol of the annealed double-stranded
oligonucleotides side-by-side to single-stranded oligonucleotides (mixed as de-
scribed in step 3) on a high-percentage (4%, w/v) agarose gel (use low-melting-point
agarose; also see step 2).
The annealed oligonucleotides should show a band at a higher molecular weight com-
pared to the single-stranded oligonucleotides. Note that single-strand oligonucleotides
will not resolve at the expected size, as they form secondary structures under non-
denaturing conditions. Estimate the proportion of annealed versus non-annealed oligonu-
cleotides: this should be >70%. Repeat steps 3 to 4 if necessary (see Troubleshooting).
6. Dilute the annealed double-stranded oligonucleotides from step 3 1: 500 in ddH2O
by performing serial dilutions of 1:10 and 1:50. Store on ice.
The diluted double-stranded oligonucleotides are not stable and should be stored on ice
or at 4°C for not more than 1 hr.
2.E: Generation of recombinant DNA
7. Assemble the following ligation reaction in a PCR tube using the Rapid DNA
Ligation Kit:
a. Cut vector from step 2 Variable volume (50 ng)
b. Diluted oligo from step 6 4 µl
c. 5× Rapid Ligation Buffer 2 µl
d. T4 DNA Ligase, 5 U/µl 1 µl
e. Ultrapure ddH2O to 10 µl
Incubate for 30 min at room temperature (22° to 25°C).
Longer incubation times are usually not required, but overnight incubation at room
temperature can be attempted if the ligation according to this protocol proves inefficient
(see Troubleshooting). An additional negative-control ligation omitting the oligo (all the
reagents above but ’b’, its volume to be replaced by ddH2O) can help in determining the
success of the molecular cloning experiment, and is recommended for first-time user or
as a troubleshooting experiment.
8. Transform 5 µl of the ligation product from step 7 into 50 µl of α-select E. coli
according to manufacturer’s instructions using a heated water bath for heat shock.
If preferred, use an equivalent highly competent and recombinase-deficient strain suitable
for plasmid propagation. Recovery of transformed bacteria at 37°C in SOC medium is
optional when using plasmids carrying an ampicillin-resistance gene, but we strongly
advise investigators to perform it, as it has been shown to improve the yield by at least
a factor of 2. Use a minimal volume of medium (100 to 250 µl) to facilitate bacterial
plating in step 9.
9. Plate all of the transformed bacteria onto a previously prepared LB agar plate
containing 100 µg/ml ampicillin and incubate overnight at 37°C in a humidified
incubator.
To facilitate the spreading of all transformed bacteria, we advise briefly centrifuging the
tube for 15 sec at 6000 × g, room temperature, discarding the supernatant by gently
pouring, and resuspending the bacterial pellet in the remaining medium (50 to 100 µl)
before plating.
2.F: Colony PCR screening of bacterial clones
10. Prepare the following PCR master mix using GoTaq Flexi DNA Polymerase (vol-
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a. siKD_fw primer (10 µM in ddH2O); Table 5C.4.1 0.5 µl
b. siKD_rev primer (10 µM in ddH2O); Table 5C.4.1 0.5 µl
c. dNTP mix (10 mM) 0.5 µl
d. MgCl2 (25 mM) 2 µl
e. 5× Green GoTaq Flexi Buffer 5 µl
f. GoTaq Flexi DNA Polymerase 0.125 µl
g. Ultrapure ddH2O 11.375 µl
Aliquot 20 µl of the reaction into PCR tubes and store on ice.
Screening of six to eight colonies per construct is recommended. If a negative control
ligation was performed during step 7, this can be used to estimate the level of background
due to self-ligated vector. If this is really low, screening of two to four colonies should be
sufficient. Since the efficiency of shRNA cloning for most sequences is very high (>90%),
colony PCR screening might be entirely bypassed (skip steps 10 to 15). If this is the
case, it is recommended to isolate six to eight clones for plasmid miniprep and confirm
successful cloning by BglII digest followed by DNA sequencing (steps 16 to 18).
11. For each clone to be analyzed, prepare two sets of sterile PCR tubes containing
200 µl of LB broth with 100 µg/ml of ampicillin, and 10 µl of ultrapure ddH2O,
respectively (use a 96 well plate if analyzing a large number of clones).
12. Using a micropipettor set on 5 µl and a sterile tip with an aerosol-barrier filter, pick
a single bacterial colony from the plate from step 9. Pipet up and down five times
into the tube with ddH2O to break down the colony, transfer 5 µl of the bacterial
suspension to the PCR tube, and pipet the remaining 5 µl to the tube with LB broth.
Change tip and repeat this step for all clones to be analyzed. At the end of this step
transfer the tubes with LB broth to 4°C storage for later use.
13. To the tube prepared for the negative control, add 5 µl of uncut pAAV-Puro_siKD
plasmid diluted to 0.2 ng/µl. This reaction will facilitate determining positive clones
based on the size of the PCR band (step 15).
14. Perform the PCR according to the following protocol:
a. 95°C 5 min
b. 95°C 30 sec
c. 60°C 30 sec
d. 72°C 1 min
Repeat steps b to d 34 times:
e. 72°C 2 min
f. 10°C hold
15. Run 7 µl of the PCR reaction on a 1.5% (w/v) agarose gel containing 0.5 μg/ml
ethidium bromide. Run at 100 V for at least 30 min, image the gel using an UV
transilluminator, and identify the clones giving a product which size is approximately
350 bp (depending on the size of the shRNA sequence; Figure 5C.4.4D).
Self-ligated vectors will result into a product of 295 bp, which can be identified from the
negative control from step 13 (Figure 5C.4.4D). If the size difference between the shRNA
containing plasmids and the empty control vector is unclear, run the gel for a longer time
until the size resolution is sufficient.
16. Inoculate the bacterial clones containing the correct ligation product using the liquid
culture from step 12 by transferring 100 µl of the bacterial suspension to a microbi-
ology tube containing 4 ml of LB broth with 100 µg/ml of ampicillin. Incubate in a
bacterial culture orbital shaker at 37°C overnight (16 hr) while shaking at 225 rpm.
We recommend expanding two to four clones in order to have some backup should the
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19). Store the bacterial plate from step 9 at 4°C for up to 2 weeks. This can be reused to
repeat steps 12 to 15 if required.
2G: Isolation and quality control of the plasmid
17. Isolate plasmids from bacterial cultures (step 16) using the QIAprep Spin Miniprep
Kit following manufacturer’s instructions. Save 200 µl of the bacterial culture at
4°C.
18. Optional: Confirm shRNA cloning by performing a diagnostic restriction digestion
with BglII using pAAV-Puro_siKD as control.
Correct recombinants containing the shRNA will not be linearized by BglII (provided no
new BglII site is found in the shRNA sequence), as this restriction site is destroyed during
the cloning. If the plasmids have been pre-screened by colony PCR (steps 10 to 15), this
step is redundant and can be omitted.
19. Perform Sanger DNA sequencing using the siKD_fw primer to confirm the presence
of the shRNA and its correct sequence.
The strong hairpin secondary structure of certain shRNAs can lead to difficulties in
Sanger sequencing. In this case, try sequencing with siKD_rev primer and ask the
sequencing company to use conditions appropriate for sequencing of GC-rich templates
or sequences with a strong secondary structure (see Troubleshooting). We recommend
using the plasmid map generated in step 7 of Basic Protocol 1 as reference to align the
sequencing results.
20. Using the liquid culture from step 17, expand the bacterial clones containing the
correct shRNA in 50 ml of LB broth with 100 µg/ml of ampicillin. Incubate in a
bacterial culture orbital shaker at 37°C overnight (16 hr) while shaking at 225 rpm.
The liquid culture from step 17 should be used within a week of storing at 4°C. Otherwise
we recommend re-transforming the plasmid from step 17, picking a fresh bacterial colony,
pre-inoculating it in 2 ml of LB broth with 100 µg/ml of ampicillin for 6 hr, and then
diluting it 1:1000 in 50 ml of LB broth to be incubated as described above.
21. Prepare a glycerol stock to be stored at –80°C for long-term backup by mixing 200 µl
of sterile autoclaved 50% (v/v) glycerol in ddH2O with 200 µl of the bacterial culture
from step 20.
Glycerol stocks can be stored for up to 10 years and used to recover the plasmid. For
this, streak the glycerol stock as in step 9 then repeat step 20.
22. Use the remaining culture to isolate the plasmid using the QIAfilter Midiprep Kit.
Resuspend the purified plasmid in elution buffer (10 mM Tris·Cl, pH 7.5 in ddH2O)
at a concentration of 500 to 1000 ng/µl and store at –20°C for up to a year.
Avoid repeated freeze-thaw cycles of the plasmid. ddH2O can be used instead of elution
buffer, but the shelf life of the plasmids will decrease. We did not notice interference of
elution buffer with the subsequent gene targeting steps. We advise using freshly prepared
plasmids (less than a month of storage) to increase the efficiency of gene targeting. We




GENERATION OF SEVERAL INDUCIBLE shRNA TARGETING VECTOR IN
PARALLEL
This alternate protocol can be followed instead of Basic Protocol 2 when several in-
ducible shRNA vectors are to be prepared simultaneously. The method is largely similar
to Basic Protocol 2 but includes a few modifications that facilitate and streamline the
procedure including: (1) the use of 96-well reaction plates and of a multichannel pipet-
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multi-compartment well plates (Figure 5C.4.2). The protocol relies on the same back-
ground information provided for Basic Protocol 2 (see Sections 2.A and 2.B in the
introduction to Basic Protocol 2) and requires the same materials and equipment, aside
from those specifically indicated below.
Additional Materials (also see Basic Protocol 2)
MicroAmp Optical 96-Well Reaction Plate (ThermoFisher, cat. no. N8010560)
MicroAmp Clear Adhesive Film (ThermoFisher, cat. no. 4306311)
8 or 12-channel pipettor appropriate for volumes between 1 and 200 µl
Sterilin 100-mm Square Petri Dishes, 25 Compartments (Dynalon, cat. no.
8700-0357
ColiRollers Plating Beads (Novagen, cat. no. 71013-3)
1. Digest, dephosphorylate, and gel extract the pAAV-Puro_siKD plasmid exactly as
described in Section 2.C (steps 1 and 2 of Basic Protocol 2).
2. Phosphorylate, anneal, and dilute the shRNA oligonucleotides as described in Section
2.D (steps 3 to 6 of Basic Protocol 2), but prepare all reactions and dilutions in a
96-well reaction plate sealed with an adhesive film. For step 6 (oligonucleotide
dilution) use a multichannel pipettor to facilitate the procedure.
3. Perform the ligation reactions as described in step 7 of Basic Protocol 2, but pre-
pare them in a 96-well reaction plate and use a multichannel pipettor to transfer
oligonucleotides. Seal the plate with an adhesive film.
4. Transform the ligations in α-Select Gold E. coli according to the following modifica-
tions of the manufacturer’s instructions.
a. Thaw the bacteria on ice and aliquot 10 µl of bacterial suspension into an ice cold
96-well plate using ice-cold tips; keep the plate on ice.
b. Using a multichannel pipettor, add 1 µl of the ligation product from step 3. Seal
the plate with an adhesive film, gently mix by tapping the plate three times, and
incubate for 30 min on ice.
c. Heat shock the bacteria by submerging the bottom of the plate in a heated water
bath set at 42°C for exactly 15 sec. Transfer on ice for 2 min, then place at room
temperature.
d. Gently remove the adhesive film, add 90 µl of SOC medium to each well using a
multichannel pipettor, and re-seal the plate. Incubate at 37°C for 1 hr (no agitation
required).
E. coli from a different source can be used if desired. In this case, we recommend
optimizing the heat-shock step timing, as in our experience this differed from the
supplier’s recommendation when using only 10 µl of bacterial suspension.
5. Plate the recombinant bacteria from step 4 onto previously prepared 25-compartment
petri dishes containing LB agar with 100 µg/ml of ampicillin. Place 20 µl and
80 µl of each bacterial suspension into two separate compartments, add two to three
glass plating beads per compartment, and shake the mix in a side-to-side motion to
evenly distribute the cells on the surface. Remove the beads by inverting the dish
and pouring them over from the lid, and incubate the dish overnight at 37°C in a
humidified incubator.
It is expected that by plating 1/5 and 4/5 of the bacterial suspension at least one of the two
conditions will result into 5 or more distinct bacterial colonies.
6. Screen the bacterial clones by colony PCR as described in Section 2.F (steps 10 to 16
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Depending on the number of plasmids to be generated, screen two to four colonies each.
7. Prepare glycerol stocks for long-term storage from small-scale bacterial cultures as
described in step 21 of Basic Protocol 2, then isolate the plasmids as described in
step 17 of Basic Protocol 2. Confirm the shRNA sequence by Sanger sequencing as
described in step 19 of Basic Protocol 2.
To simplify the workflow when many plasmids are generated in parallel, minipreps can
be used directly for gene targeting experiments at the expense of a reduced targeting
efficiency. Alternatively, perform plasmid midipreps to obtain DNA of better quality (steps
20 to 22 of Basic Protocol 2).
SUPPORT
PROTOCOL 1
GENERATION OF TARGETING VECTOR WITH MULTIPLE INDUCIBLE
shRNAs
This optional protocol outlines a method to produce a single OPTiKD AAVS1 target-
ing vector carrying multiple inducible shRNAs to be co-expressed in the same cell
(Figure 5C.4.2 and Figure 5C.4.5A). Such an approach allows simultaneous knock-
down of multiple genes in order to study complex biochemical pathways involving more
than one gene. Alternatively, the method can be applied to co-express several distinct
shRNAs targeting different portions of the same transcript in order to increase the level
of knockdown.
S1.A: Assembly of the multiple shRNA vector
This approach relies on having first cloned the desired shRNA sequences in the pAAV-
Puro_siKD vector as described in Basic Protocol 2 or the Alternate Protocol. Then,
inducible shRNA cassettes are assembled into a single plasmid by a one-step seamless
Gibson cloning assembly reaction (Gibson et al., 2009). This method involves isother-
mal joining of multiple DNA fragments sharing specific sequence overlaps at the 5′- and
3′-ends (Figure 5C.4.6A). Individual inducible shRNA expression cassettes (consisting
of the H1-TO promoter and the shRNA sequence) are amplified by DNA polymerase
chain reaction (PCR) using primers that introduce specific sequences at the 5′ and 3′-end
to create 20- to 39-bp-long sequence overlaps with the plasmid or the various fragments
to be assembled. Such overlaps are designed to allow directional assembly of the mul-
tiple shRNA cassettes in the desired order. Using this approach, we have successfully
assembled OPTiKD plasmids carrying two or three inducible shRNAs, a procedure de-
scribed in the following protocol, but we anticipate that the method could be scaled up
to assemble up to six to eight shRNAs. After the assembly, each pair of joined frag-
ments is separated by a 105-bp spacer sequence consisting of a 75-bp common fragment
resulting from PCR amplification of the plasmid backbone plus a pair-specific 30-bp
sequence introduced by the primers used for PCR (Table 5C.4.1). By physically separat-
ing the shRNA cassettes, such a spacer sequence minimizes transcriptional interference.
We refer to the pair-specific 30-bp sequence as “block” or “BL,” with BL1 separat-
ing the first and second shRNA in a 2- or 3-way assembly, and BL 2 separating the
second and third shRNAs in a 3-way assembly (Table 5C.4.2). The nucleotide composi-
tions of BL1 and BL2 are 5′-ACTATGCTGTGTCTTGACAGCAGACCTCGT-3′ and
5′-TGGACACACAAGTACTGTCGGCAACCACAC-3′, respectively (Table 5C.4.1).
Usage of alternative block sequences would allow assembly of more than three shRNAs
(Wang, Shi, Liu, Jules, & Feng, 2006).
Materials
pAAV-Puro_siKD plasmid [Addgene, cat. no. 86695; alternatively contact the
corresponding authors (abertero@uw.edu; lv225@cam.ac.uk)]
FastDigest Bsp119I (ThermoFisher, cat. no. FD0124)
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Figure 5C.4.5 Generation of OPTiKD vectors containing multiple shRNAs. (A) Schematic of the
cloning procedure described in Support Protocol 1. On the top, the location of primer annealing
portions is shown with arrows that indicate their 5′-3′ directionality, while the non-annealing portions
are shown in colored boxes. 5′/3′: overlap to the 5′- and 3′-portion of the cut vector; BL1/2: block
sequences providing the necessary overlaps for directional Gibson assembly. The steps involved in
Gibson assembly of the PCR-amplified shRNA cassettes with the cut vector are indicated. On the
bottom, the location of primers for colony PCR and sequencing are shown on the final construct.
(B) Representative example of colony PCR results from 22 screened clones after assembly of
three shRNA cassettes. Clones with the expected amplification product are indicated. Neg control:
PCR performed on pAAV-Puro_siKD (indicating the size of vectors with only one shRNA cassette).
Note that the second screened clone from the left likely integrated only two of the three shRNA
cassettes due to erroneous assembly.
pAAV-Puro_siKD-shRNA (with custom shRNAs of interest; Basic Protocol 2)
Q5 Hot Start High-Fidelity 2× Master Mix (New England Biolabs, cat. no.
M0494S)
5′_fw (custom oligonucleotide, see Table 5C.4.1)
BL1_fw (custom oligonucleotide, see Table 5C.4.1)
BL2_fw (custom oligonucleotide, see Table 5C.4.1)
BL1_rev (custom oligonucleotide, see Table 5C.4.1)
BL2_rev (custom oligonucleotide, see Table 5C.4.1)
3′_rev (custom oligonucleotide, see Table 5C.4.1)
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Table 5C.4.2 Oligonucleotide Combinations for PCR of Inducible shRNA Cassettes to be As-
sembled by Gibson Assembly
Assembly of 2 shRNAs
shRNA Primer fw Primer rev Fragment
First shRNA (sh1) 5′_fw BL1_rev 5′_sh1_BL1
Second shRNA (sh2) BL1_fw 3′_rev BL1_sh2_3′
Assembly of 3 shRNAs
shRNA Primer fw Primer rev Fragment
First shRNA (sh1) 5′_fw BL1_rev 5′_sh1_BL1
Second shRNA (sh2) BL1_fw BL2_rev BL1_sh2_BL2
Third shRNA (sh3) BL2_fw 3′_rev BL2_sh3_3′
1.5% (w/v) agarose gel in TBE containing 0.5 μg/ml ethidium bromide (see recipe)
NEBuilder HiFi DNA Assembly Cloning Kit (New England Biolabs, cat. no.
E5520S)
MsiKD_fw (custom oligonucleotide, see Table 5C.4.1)
BL1seq_fw (custom oligonucleotide, see Table 5C.4.1)
BL2seq_fw (custom oligonucleotide, see Table 5C.4.1)
MsiKD_rev (custom oligonucleotide, see Table 5C.4.1)
FastDigest NdeI (ThermoFisher, cat. no. FD0583)
Additional reagents and equipment for molecular cloning experiments (see Basic Proto-
col 2)
S1.B: Preparation of cloning vector
1. Digest pAAV-Puro_siKD by preparing the following reaction:
a. pAAV-Puro_siKD Variable volume (5 µg)
b. FastDigest Bsp119I 5 µl
c. FastDigest HincII 5 µl
d. FastDigest Green Buffer (10×) 10 µl
e. Ultrapure ddH2O to 100 µl
Incubate for 1 hr and 30 min at 37°C.
Bsp119I is a isoschizomer of BstBI, which can be alternatively used if preferred. Refer to
step 1 of Basic Protocol 2 for additional considerations on restriction enzyme digestion
and storage of the cut plasmid that also apply to this step.
2. Gel-extract the digested plasmid following electrophoretic run as described in step
2 of Basic Protocol 2, but excising the 9246-bp band.
A fainter 241-bp band corresponding to the excised H1-TO promoter should be visible
upon successful plasmid digestion. Refer to step 2 of Basic Protocol 2 for additional
considerations that also apply to this step.
S1.C: Preparation of shRNA inserts
3. Refer to Table 5C.4.2 to identify the primer combinations to generate the PCR
fragments with the required overlaps for directional Gibson assembly.
Table 5C.4.2 lists primer pairs for fragments to be used in assembly of two or three
shRNAs. If four or more shRNAs are to be assembled, additional primers will need to
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4. For each shRNA cassette to be amplified, use the corresponding pAAV-Puro_siKD-
shRNA vector (Basic Protocol 2) as template in the following reaction mix:
a. pAAV-Puro_siKD-shRNA Variable volume (4 ng)
b. Q5 Hot Start High-Fidelity 2× Master Mix 100 µl
c. Forward primer (5 µM in ddH2O), Table 5C.4.1 10 µl
d. Reverse primer (5 µM in ddH2O), Table 5C.4.1 10 µl
e. Ultrapure ddH2O to 200 µl
5. Aliquot the reaction into four PCR tubes with 50 µl each and run the PCR in a
thermocycler according to the following program (lid kept at 95°C):
a. 98°C 1 min
b. 98°C 10 sec
c. 65°C 30 sec
d. 72°C 30 sec
Repeat steps b to d for 34 cycles
e. 72°C 30 sec
f. 10°C hold
6. Pool the four reactions, purify the DNA using the QIAquick PCR Purification Kit
according to the manufacturer’s instructions, and confirm successful amplification
by running 200 ng of the resulting DNA on a 1.5% agarose gel (Basic Protocol 2,
step 2).
A sharp band at approximately 400 bp (depending on the fragment and shRNA sequence)
should be visible. Fainter nonspecific amplification bands at lower molecular weights
and some residual primer sequences might be present, but are not problematic provided
that they can be clearly distinguished from the fragment of interest.
7. Gel-extract 2 µg of DNA for each fragment following the electrophoretic run as
described in step 2 of Basic Protocol 2, but using a 1.5% (w/v) agarose gel and
excising the band at approximately 400 bp.
If nonspecific amplification bands or residual primers are present make sure to run the
electrophoresis long enough so to clearly separate them from the fragment of interest. Co-
extraction of such unwanted DNA will significantly reduce the efficiency of the assembly
step.
S1.D: Generation of recombinant DNA
8. Prepare the following Gibson assembly reaction in a PCR tube using the NEBuilder
HiFi DNA Assembly Cloning Kit:
a. Cut vector from step 2 variable volume (150 ng)
b. shRNA cassette 1 PCR fragment from step 7 variable volume (35 ng)
c. shRNA cassette 2 PCR fragment from step 7 variable volume (35 ng)
d. shRNA cassette 3 PCR fragment from step 7 variable volume (35 ng)
e. NEBuilder HiFi DNA Assembly Master Mix (2×) 10 µl
f. Ultrapure ddH2O to 20 µl
Incubate for 1 hr at 50°C in a thermocycler
In the case where only two shRNAs are to be assembled, omit reagent d from the above
mix. For assemblies of more than four shRNAs, the conditions might need to be adjusted
according to the supplier’s recommendations regarding the maximum pmol of DNA to
be used in each reaction. A larger reaction volume might also be required. A negative
control assembly omitting reagents b, c, and d can be performed to evaluate the potential
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9. Transform 2 µl of the assembly product from step 8 into 50 µl of NEB 5-alpha
E. coli (provided with the NEBuilder HiFi DNA Assembly Cloning Kit) according
to manufacturer’s instructions using a heated water bath for heat shock.
10. Plate 10% of the transformed bacteria onto a previously prepared LB agar plate
containing 100 µg/ml of ampicillin and incubate overnight at 37°C in a humidified
incubator
A yield of more than 50 colonies is to be expected. Store the remaining bacterial suspen-
sion at 4°C as backup.
S1.E: Colony PCR screening of bacterial clones
11. Assemble colony PCR reactions according to steps 10 to 13 of Basic Protocol 2, but
using MsiKD_fw and MsiKD_rev primers (Table 5C.4.1).
Screening of 8 to 12 colonies is recommended. As an alternative to colony PCR, plasmids
can be screened by restriction digestion ( step step 16, below). In this case, proceed
directly to step 14, below, but inoculate 8 to 12 randomly chosen bacterial colonies.
12. Perform PCR according to the protocol described in step 14 of Basic Protocol 2,
but increase the timing of step d (extension) to 2 min to accommodate for the larger
product.
13. Run PCR reaction product on a 1.5% agarose gel as described in step 15 of Basic
Protocol 2, but identify clones giving a product size of approximately 1200 bp
(assembly of two shRNAs) or 1600 bp (assembly of three shRNAs; Figure 5C.4.6B).
Plasmids resulting from rare events of inappropriate assemblies or from contaminating
undigested plasmid will result in products of approximately 700 to 800 bp (single shRNA
cassette) or 1200 bp (two shRNA cassettes) and should be discarded (Figure 5C.4.6B).
14. Inoculate the bacterial clones containing the correct ligation product as described in
step 16 of Basic Protocol 2.
S1.F: Isolation and quality control of the plasmid
15. Isolate plasmids from bacterial cultures as described in step 17 of Basic Protocol 2.
16. Optional: Confirm the success of Gibson assembly by performing a diagnostic
restriction digestion with Bsp119I and NdeI.
Correctly assembled plasmids will release a restriction fragment of approximately 1000
bp (assembly of two shRNAs) or 1350 bp (assembly of three shRNAs). If the plasmids
have been pre-screened by colony PCR (steps 11 to 13 of this protocol), this control is
redundant and can be omitted.
17. Perform Sanger sequencing analyses using MsiKD_fw, BL1seq_fw, and BL2seq_fw
(Table 5C.4.1; Figure 5C.4.6A) to confirm the presence of the shRNA cassettes and
their correct sequence.
Refer to step 19 of Basic Protocol 2 for advice on sequencing shRNAs. If required, also use
the primer MsiKD_rev. To facilitate the analysis of sequencing results, we recommend
creating a reference plasmid map by using SnapGene (or an equivalent software) to
simulate in silico the cloning steps performed in steps 1 to 8.
18. Propagate, purify, and create a long-term stock of the plasmid (named pAAV-
Puro_MsiKD-shRNAs) as described in steps 20 to 22 of Basic Protocol 2.
BASIC
PROTOCOL 3
GENERATION OF OPTIKD hPSCs
In this third part of the procedure, the targeting vector with the inducible shRNA(s) is
integrated into the AAVS1 locus to generate OPTiKD hPSCs (Figure 5C.4.6A). First,
hPSCs are co-transfected with the targeting vector and two AAVS1 ZFN plasmids.
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Figure 5C.4.6 Generation of OPTiKD hPSCs. (A) Schematic of the gene targeting procedure described in Basic
Protocol 3. The resulting OPTiKD transgenic allele and its functionality in presence or absence of tetracycline (TET)
are shown. ZFN: zinc finger nuclease; i-shRNA: inducible shRNA; iKD: inducible knockdown; KD: knockdown. (B)
Schematic of the AAVS1 gene-targeting event that generates the OPTiKD transgenic allele through homologous re-
combination of the donor plasmid. The genotyping strategies used to identify correctly targeted hPSCs are shown
(Support Protocol 2). Locus PCR: PCR product of wild-type AAVS1 locus (indicating a non-targeted allele); Loss-of-
allele: potential PCR amplification that fails onto the targeted allele due to large size and high GC-content; 5′/3′-INT
PCR: PCR product of transgene 5′/3′-end integration region (indicative of expected transgene targeting); 5′/3′-BB PCR:
PCR product of vector backbone 5′/3′-end (indicative of nonspecific off-target plasmid integration). Refer to the legend of
Figure 5C.4.2 for additional abbreviations found in panels A-B. (C) Location of the binding sites for the AAVS1 ZFN. FokI
ELD/KKR: mutant obligate heterodimer FokI endonuclease domains (Section 3.A; see Basic Protocol 3 introduction).
(D-K) Representative phase-contrast images of hPSCs at the indicated stages of the gene targeting procedure. Scale
bars: 1000 μm. (L) Representative example of genotyping results from 12 screened OPTiKD clonal sublines (refer to
panel B and Table 5C.4.4). The inferred genotypes are indicated (Table 5C.4.3). Hom: homozygous; Het: heterozygous;
+: off-target plasmid integration. WT: control PCR from wild-type hPSCs; Plasmid: control PCR from pAAV-Puro_siKD
plasmid.
untargeted cells. The resulting OPTiKD cells can be used for experimental purposes
either directly as a pool arising from various targeting events or after clonal selection of
individual sublines (Support Protocol 2).
3.A: Gene targeting of the AAVS1 locus
As introduced in Section 2.A (see introduction to Basic Protocol 2), selective integra-
tion of the targeting vector into the AAVS1 locus is facilitated by ZFNs, which induce
site-specific double-strand breaks that are then repaired by HDR using the targeting
vector as template (Figure 5C.4.6B). This leads to integration of the transgenic cassette
placed between the two homology arms, which contains all functional elements of the
OPTiKD method. The ZFN-based gene targeting procedure was originally described
by the Jaenisch laboratory (Hockemeyer et al., 2009), which also developed a similar
approach based on Transcription Activator-Like Effector Nucleases (TALENS; Hocke-
meyer et al., 2011). More recently, analogous strategies based on Clustered Regularly
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reported (Mali et al., 2013; Oceguera-Yanez et al., 2016; Sim, Cardenas-Diaz, French,
& Gadue, 2015). In all cases, the engineered nucleases recognize a very similar (if not
identical) sequence between exons 1 and 2 of the PPP1R12C gene on human chromo-
some 19.
Our protocol relies on a modified version of the original ZFN-based method by Jaenisch
and colleagues (Hockemeyer et al., 2009). ZFNs consist of two functional domains:
a DNA-binding domain, which is classically constituted by two or more two-finger
modules each recognizing a hexamer sequence, and a DNA-cleaving domain comprising
the nuclease domain of FokI (Gaj et al., 2013). Such a domain must dimerize in order
to cleave the DNA, and thus a pair of adjacent ZFNs each targeting opposite DNA
strands are required in order to induce a double-strand break (Figure 5C.4.6C). In our
method, the original ZFN plasmids have been modified in the following ways: (1) the
two FokI domains carry respectively the ELD (Q486E, I449L, and N496D) and KKR
(E490K, I538K, and H537R) mutations, which provide superior cleavage activity while
minimizing nonspecific cleavage by suppressing homodimerization (Doyon et al., 2011);
(2) the ZFN cDNAs were codon-optimized for mammalian expression, which increases
the steady-state protein expression; (3) the ZFNs are expressed under the control of the
strong cytomegalovirus (CMV) promoter, which ensures rapid and transient expression
upon transfection. The resulting plasmids (pZFN_AAVS1-L-ELD and pZFN_AAVS1-
R-KKR) are approximately 4 kbp long, and should be expanded in transformed bacteria
cultured in presence of 50 µg/ml kanamycin. These recommended plasmids are available
upon request from the corresponding authors. The plasmid repository Addgene offers
alternative ZFNs (#60915 and #60916; Sim et al., 2015) and TALENs (#59025 and
#59026; González et al., 2014) that are compatible with our targeting vector, as they
induce double-strand breaks in the same genomic region. Plasmids for CRISPR/Cas9
editing of the AAVS1 locus are also available from Addgene, but in this case modifications
of the targeting vector might be required to ensure that these will not be cut by the
Cas9 protein (for instance by mutating the protospacer adjacent motif sequence). If
using nucleases different from the ones we recommend, the gene editing procedure
might need to be re-optimized, in particular the ratio of nuclease plasmids to targeting
vector.
3.B: Plasmids delivery and selection of gene targeted lines
The two AAVS1 ZFN plasmids and the targeting vector must be co-expressed to ini-
tiate gene targeting (Figure 5C.4.6A). For this, we recommend the use of GeneJuice,
a non-lipid-based chemical transfection reagent which is minimally toxic to hPSCs
(Figure 5C.4.6F). With the cost-effective and simple method described in the following
protocol we routinely achieve 20% to 40% transfection efficiency with >80% survival
in a number of hPSC lines. Alternatively, we have also successfully used cationic-lipid-
based transfection reagents such as Lipofectamine 2000 (Bertero et al., 2016), albeit the
toxicity of this method proved significant in certain hPSC lines. Finally, nucleofection
represents another valid option that allows higher efficiency of plasmid delivery (up to
70%; Bertero et al., 2016) at the expense of decreased cell survival (50% or less), need
for specialized equipment, and increased costs. Therefore, we only recommend nucle-
ofection as a backup approach to improve plasmid delivery should initial transfection
experiments prove inefficient in a certain hPSC line. Regardless of the method of prefer-
ence, it is of crucial importance to achieve plasmid delivery in at least 20% of the cells
in order to maximize the efficiency of gene targeting (see Commentary).
Following transfection, hPSCs are grown for a few days to allow successfully targeted
cells to form a small sub-colony of 8 to 64 cells, as this will promote their survival
during the subsequent drug selection step (Figure 5C.4.6G). Gene-targeted hPSCs are
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(see introduction to Basic Protocol 2), the OPTiKD transgenic cassette includes a gene
trap–based puromycin resistance gene (PAT) whose expression is driven by the endoge-
nous promoter found in the AAVS1 locus (PPP1R12C gene). In our experience, the
dosage of puromycin required to complete selection while inducing minimal toxicity in
gene-targeted cells is similar across different hPSC lines (0.4 to 1.2 µg/ml). However, we
recommend testing this aspect in each new line by performing a drug-sensitivity exper-
iment. In addition to puromycin, the ROCK inhibitor Y-27632 can be added during the
first 2 days of selection in order to promote survival of the small colonies of gene targeted
cells (Watanabe et al., 2007). The vast majority of hPSCs will die following puromycin
selection, and a number of small colonies should appear and gradually grow over the
subsequent days of culture (Figure 5C.4.6H to J). Since the efficiency of targeting using
this method is extremely high, with more than 95% of clonally isolated lines showing
the expected transgene in the AAVS1 locus (Bertero et al., 2016), the resulting OPTiKD
hPSCs can be used directly for experimental purposes. Alternatively, individual clonal
sub-lines can be isolated to generate a homogeneous population (Figure 5C.4.6K), an
optional procedure described in Support Protocol 2. Once drug selection is complete,
addition of puromycin to the medium is not required, and depends upon user preference.
Indeed, we have not observed silencing of the OPTiKD transgene even upon prolonged
culture for up to 20 passages.
3.C: Culture conditions
The following protocol was optimized for hPSCs maintained in Essential 8 (E8), a
commonly used and commercially available medium for hPSC culture in feeder-free,
chemically defined, and xeno-free conditions (Chen et al., 2011). The protocol further
relies upon seeding hPSCs on tissue culture dishes pre-coated with recombinant human
Laminin-521, a physiological, chemically defined, and xeno-free substrate that supports
optimal attachment and growth of genetically stable hPSCs (Lu et al., 2014; Rodin et al.,
2014). In our experience, these conditions maximize both the speed and efficiency when
generating OPTiKD cells. We have also successfully generated feeder-free OPTiKD hP-
SCs in cells maintained in a chemically defined media containing bovine serum albumin
(CDM-BSA) or polyvinyl acid (CDM-PVA) and seeded upon culture dishes coated with
FBS and gelatin (Bertero et al., 2016; Vallier, 2011). Thus, we anticipate that the pro-
cedure described below will be applicable in a wide range of feeder-free hPSC culture
conditions following potential minor optimizations. Should feeder-dependent culture of
hPSCs be preferable to the user, more extensive modifications to the protocol might be
required, including the use of puromycin resistant mouse embryonic fibroblasts (MEFs)
such as DR4 MEFs.
The protocol below describes the procedure to generate OPTiKD hPSCs from cells
cultured and transfected in a 6-well plate format. Successful transfection of a single
well of 6-well plate should result in at least five colonies following drug selection
(range of 5 to 100 depending on the cell line). However, when possible, we recommend
transfecting two to three wells for each inducible shRNA in order to maximize the
chances of success. In this case, the different wells can serve as biological replicates
during subsequent experiments. If clonal isolation of OPTiKD sub-lines is preferred,
having multiple wells each containing a few (5 to 20) clearly distinguishable colonies
facilitates picking while minimizing potential for multiclonality in any given colony.
Nevertheless, the protocol can be scaled to different plate formats (both larger and
smaller) with minimal optimization. For instance, we have successfully scaled down
volumes and plasmid quantities in the procedure described below to generate OPTiKD
hPSCs in a 12-well plate format, which simplifies the generation of multiple OPTiKD
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Materials
Human pluripotent stem cells (hPSCs; user specific; see appropriate units in this
manual)
Complete Essential 8 (E8) medium (see recipe)
Opti-MEM reduced serum medium with GlutaMAX (ThermoFisher, cat. no.
51985034)
Dulbecco’s phosphate-buffered saline (DPBS) without calcium and magnesium
(ThermoFisher, cat. no. 14190250)
Versene solution (ThermoFisher, cat. no. 15040066)
10 mM Y-27632 stock solution (see recipe)
0.4% trypan blue (ThermoFisher, cat. no. 15250061)
GeneJuice transfection reagent (EMD Millipore, cat. no. 70967)
pZFN_AAVS1-R-KKR [contact the corresponding authors (abertero@uw.edu;
lv225@cam.ac.uk)]
pZFN_AAVS1-L-ELD [contact the corresponding authors (abertero@uw.edu;
lv225@cam.ac.uk)]
pAAV-Puro_siKD-shRNA or pAAV-Puro_MsiKD-shRNAs (Basic Protocol 2,
Alternate Protocol, or Support Protocol 1)
AAVS1-CAGGS-EGFP (Addgene, cat. no. 22212)
10 mg/ml puromycin dihydrochloride (Sigma Aldrich, cat. no. P9620-10ML)
Recombinant human Laminin-521-coated 6-well culture plates (see recipe)
15-ml conical centrifuge tubes
Inverted microscope equipped with fluorescent lamp and filters for FITC (EGFP)
detection
Hemacytometer
Additional reagents and equipments for culture of human pluripotent stem cells (Costa
et al., 2008)
3.D: Preparatory steps
1. Grow hPSCs to 50% to 60% confluence in complete E8 medium without antibiotics
on 6-well plates coated with Laminin-521 (Figure 5C.4.6D). Maintain cells in an
incubator with 5% CO2 and 95% humidity.
Cells to be used for transfection should be subconfluent and within their exponential
growth phase for optimal transfection. Estimate the necessary cell amount based on the
number of wells to be transfected (300,000 cells per well; step 8). Antibiotics are toxic
during transfection due to the increased cell membrane permeability. Therefore, it is
recommended to omit them from the culture medium for at least 2 days both before and
after transfection.
2. On the day before setting up the transfection, pre-coat overnight new 6-well plates
with Laminin-521 as described in Reagents and Solutions.
We recommend preparing two to three wells for each inducible shRNA targeting vector
to be transfected (Section 3.C; see introduction to Basic Protocol 3). A mock transfection
without any plasmids is recommended as a negative control to monitor the efficiency of
drug selection (step 13). Finally, a transfection using AAVS1-CAGGS-EGFP (to be used
instead of pAAV-Puro_siKD-shRNA) is also recommended as positive control, as it will
allow monitoring transfection and gene targeting efficiency by visual inspection of EGFP
fluorescence (steps 11 to 13). For both these controls, a single well is sufficient.
3. Pre-warm the new Laminin-521 coated plates in the incubator, allow Opti-MEM
and E8 to reach room temperature, thaw and gently mix the plasmids and Y-27632,
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3.E: Collection of hPSCs
4. Aspirate hPSC culture medium, rinse the cells with 2 ml of DPBS without calcium
and magnesium, and incubate in 2 ml of Versene for 3 to 6 min at 37°C in the
incubator until colonies are ready for mechanical passaging.
Volumes are for one well of 6-well plate. The EDTA contained in Versene chelates divalent
ions such as calcium and magnesium, thus inhibiting cell-cell and cell-matrix contacts.
The timing of Versene incubation is dependent on the cell line and growth conditions and
must be adjusted empirically. When monitored under the microscope, the edges of hPSC
colonies must be lifting while cells at the center of the colonies must be rounding up.
However, do not wait until the whole colony is lifting.
5. Gently aspirate Versene and mechanically lift cells by adding 1 ml of complete E8
supplemented with 10 µM Y-27632 (E8+Y). Gently pipet up and down five to ten
times to mechanically triturate the colonies and transfer to a 15-ml conical tube.
Wash the well once with 1 ml of E8+Y to collect residual cells and transfer to the
same conical tube.
Before lifting the cells, confirm that the colonies are readily detaching from the plate by
gently tapping it on the side. If necessary, add 100 µl of Versene and incubate the cells
at room temperature for up to 5 min. When lifting the cells, add medium gradually and
proceed from the bottom to the top of the well to prevent the calcium found in E8 from
inactivating Versene in cells that have not been yet mechanically detached.
6. Inspect an aliquot of the cell suspension under the microscope to confirm dissociation
to near single cells. If necessary, triturate again by gently pipetting 5 to 10 times.
Aim to generate a suspension with approximately 50% single cells while the rest are found
in small clumps of 2 to 10 cells (Figure 5C.4.6E). Do not over-triturate and minimize
mechanical stress on the cells.
7. Dilute 50µl of cell suspension in an equal volume of trypan blue solution and perform
live cell count using a hemacytometer. Dilute the cell suspension to 150,000 live
cells/ml in E8+Y.
hPSC viability should be >95%. Prepare sufficient volume for the number of wells to be
plated (plus some extra to account for pipetting errors); 300,000 cells are required for
each condition.
3.F: Transfection of hPSCs
8. Remove the excess Lamin-521 coating solution from pre-coated 6-well plates (step
1) and immediately aliquot 300,000 hPSCs per well in a volume of 2 ml. Gently
transfer the plate to the incubator.
Do not let the coated surface dehydrate, as this will inactivate the Laminin-521 coating.
When plating the cells, avoid creating turbulences that can lead to uneven plating by
gently pipetting the cell suspension. Do not shake the plate to prevent cell clumping in
the middle of the well.
9. For each well to be transfected, prepare the transfection mix according to the fol-
lowing steps:
a. Add 6 µl of GeneJuice to 100 µl of Opti-MEM in a microcentrifuge tube.
b. Immediately mix by vortexing at maximum speed for 3 sec.
c. Incubate at room temperature for 5 min.
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a. Immediately mix by pipetting 3 to 5 times. Do not vortex
b. Incubate at room temperature for 15 min.
Once prepared, the transfection mix is stable for up to 30 min at room temperature. When
transfecting multiple wells with the same inducible shRNA plasmid, prepare a master
mix by scaling the volumes above accordingly. We recommend performing a negative
control transfection omitting all plasmids and a positive control transfection using AAV-
CAGGS-EGFP instead of pAAV-Puro_siKD-shRNA (step 1). Finally, a transfection with
pAAV-Puro_siKD-shRNA alone can be performed to validate the functionality of ZFN
plasmids. This should result in no or very few colonies, which are the result of rare events
of random plasmid integration into an active gene, compared to the large number of
colonies obtained when including the ZFN plasmids, the result of correct AAVS1 gene
targeting events. However, we recommend this control only as a potential troubleshooting
measure.
10. Pipet the transfection mix drop-by-drop onto the hPSCs from step 8. Cover all the
well surface by following a spiral pattern from the outside to the inside to ensure
homogeneous dispersion. Transfer the plate to the incubator and gently rock back
and forth, left and right two to three times to further distribute the transfection mix.
Incubate overnight (16 to 20 hr).
hPSCs readily adhere to Laminin-521 and should be firmly attached to the bottom of the
plate at this stage.
3.G: Selection of gene targeted hPSCs
11. On the day following transfection, aspirate the culture medium, gently rinse the cells
once with 2 ml of DPBS without calcium and magnesium, and add 2 ml of fresh
complete E8 medium.
From here onwards, the culture medium must be replaced daily without any cell wash
unless stated otherwise.
Inspect the cells to confirm lack of bacterial contamination. There should be very little
toxicity due to the transfection reagent, with most of the cells being attached and forming
small colonies (Figure 5C.4.6F). hPSCs might look spindle-shaped at this stage, but
the morphology will improve following removal of ROCK inhibitor from the medium. If
a positive control transfection with AAV-CAGGS-EGFP has been performed (step 9),
EGFP fluorescence should be readily detectable in at least 20% of the cells.
12. After approximately 48 hr (on the third day following transfection), begin selection
by adding 1 µg/ml puromycin to the culture medium.
Selection should be started when the cells reach approximately 50% to 70% confluence
[Section 3.B (see introduction to Basic Protocol 3); Figure 5C.4.6G]. If a positive-control
transfection with AAV-CAGGS-EGFP has been performed (step 9), EGFP-positive clus-
ters of 8 to 32 cells should be visible. The optimal dose of puromycin should be determined
for every new cell line (Section 3.B; see introduction to Basic Protocol 3). Puromycin
should be added to the medium from now on except when passaging the colonies (step 14),
in order to avoid excessive stress on single cells. Once the OPTiKD hPSC line has been
established and banked puromycin can be withdrawn (Section 3.B; see introduction to
Basic Protocol 3). Addition of 10 µM Y-27632 (ROCK inhibitor) during the first 48 hr of
selection can increase survival of gene targeted colonies.
13. After approximately 48 hr (on the fifth day following transfection) selection should
be completed (Figure 5C.4.6H to I).
All cells should be dead in the negative control transfection without the targeting plasmid
(step 9). If a positive control transfection with AAV-CAGGS-EGFP has been performed
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14. After approximately 2 to 5 days (on the seventh to tenth day following transfec-
tion), individual hPSC colonies will reach an appropriate size for passaging (500 to
1000 µm; Figure 5C.4.6J). The resulting OPTiKD hPSCs can be directly used for
validation and experimental purposes (Basic Protocol 4). Alternatively, they can first
be clonally isolated (Support Protocol 2).
The growth rate will be cell-line dependent and certain hPSCs might require up to 20 days
following transfection to reach this stage. If multiple wells have been transfected with the
same inducible shRNA vector, we advise keeping them separate as biological replicates.
The OPTiKD line should be expanded and banked for long-term storage in liquid nitrogen
as soon as possible. Furthermore, it is recommended to perform standard quality controls
such as karyotyping and testing to exclude mycoplasma contamination.
SUPPORT
PROTOCOL 2
CLONAL ISOLATION AND GENOTYPING OF OPTIKD hPSCs
This optional protocol describes the generation of clonal OPTiKD hPSC lines in which
the AAVS1 gene targeting event is confirmed at the genomic level while off-target random
integration of the targeting vector is excluded. Individual gene-targeted colonies are first
mechanically picked and expanded into clonal sublines, and then subjected to extensive
DNA genotyping by PCR.
S2.A: Advantages and disadvantages of clonal isolation
As introduced in Section 3.B (see introduction to Basic Protocol 3), this step is not
strictly required given the high efficiency in generating correctly gene-targeted lines
according to Basic Protocol 3. However, we recommend considering this additional
procedure if the cells will be used for experiments at the single-cell level and it will
be impractical or impossible to distinguish correctly targeted inducible knockdown cells
from contaminating wild-type hPSCs. Furthermore, this procedure can be advantageous
if the level of knockdown observed following induction of the shRNA in non-clonal
OPTiKD hPSCs is less than 75%, as clonal isolation allows selection of the OPTiKD
hPSCs sublines with maximal knockdown efficiency across the targeted pool. Finally, this
additional step is most useful to maximize experimental success when gene knockdown
is to be initiated at a stage of hPSC differentiation that is subsequent to the one in which
the efficiency of gene knockdown has been initially validated. Indeed, only copies of the
inducible shRNA transgene that have been integrated into the AAVS1 locus will support
consistent inducible gene knockdown across a wide range of lineages (Bertero et al.,
2016). On the contrary, randomly integrated transgenic copies can be transcriptionally
active at early but not late stages of hPSC differentiation due to silencing events associated
to chromatin remodeling initiated by cell-fate choices. Therefore, not considering the
potential for random integration of the targeting plasmid could result in an overestimation
of the level of knockdown that can be achieved only by means of the correctly targeted
inducible shRNA transgenes.
On the other hand, clonal isolation of hPSCs has one main disadvantage in that it in-
creases the likelihood of observing line-to-line variability across sublines due to distinct
genetic and epigenetic features. This drawback is somewhat mitigated in OPTiKD lines
since uninduced cells maintained in the absence of tetracycline will serve as internal
controls that allow evaluation of such potential intrinsic line-to-line variability (Basic
Protocol 4). Nevertheless, we recommend that when clonal isolation is preferable for
one of the reasons listed above, at least two clones for each inducible shRNA should be
functionally analyzed to ensure that any given phenotype is reproducible across multi-
ple sublines. Finally, karyotyping of clonally isolated sublines is of utmost importance
to identify potential aneuploid lines and exclude them from experimental analyses. In-
deed, the appearance of karyotypic abnormalities following gene-targeting experiments is GeneticManipulation of
Stem Cells
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unfortunately not uncommon due to both the strong selective pressure that is imposed on
the cells during drug selection and the single-cell growth requirement of the procedure.
S2.B: Clonal isolation of OPTiKD sublines
OPTiKD sublines can be isolated by manually picking gene-targeted colonies obtained
from the procedure described in Basic Protocol 3. For this, it is best to transfect cells
in the 6-well format recommended by the protocol or even to use a larger plate, both
to simplify picking and to maximize the spacing among colonies. Even so, it should be
noted that this approach does not formally ensure clonality of the derived sublines, since
any colony could have resulted from two independent targeting events in cells that were
in close proximity. Moreover, hPSCs can extensively migrate across nearby colonies
over prolonged culture. Nevertheless, both of these events are relatively rare provided
that the colonies are monitored immediately after puromycin selection in order to mark
for exclusion those that are found in too close proximity (less than 1 to 2 mm). Therefore,
in this protocol, we still use the word “clonal” when referring to the pseudo-clonal lines
that can be isolated using this method. A more stringent way to generate clonal lines
would be to seed hPSCs into 96- or 384-well plates at limiting dilution of one cell per
well or following cell sorting of individual cells. However, these approaches are very
time consuming, and thus we recommend them only as a backup option should there be
any doubts regarding the clonality of the sublines. Another alternative to the approach
outlined below is to seed a small number of single cells into a large petri dish, for instance
1,000 to 5,000 cells in a 100-mm-diameter dish, so that they might grow into individual
colonies. While this method suffers from similar limitations to the one we propose and
the resulting colonies are still pseudo-clonal, it can prove advantageous if the colonies
from Basic Protocol 3 are too densely packed to ensure robust clonal isolation. Moreover,
such strategy can allow subsequent clonal isolation of lines that have not been initially
processed according to the protocol below.
S2.C: Genotyping of OPTiKD sublines
Following clonal isolation, we recommend that OPTiKD hPSCs be genotyped by PCR.
Indeed, while functional validation of OPTiKD hPSCs by quantitative real-time PCR
(qPCR) and/or western blot will serve in most circumstances (Basic Protocol 4), the
advantage of having a clonally isolated line is maximized when the genotype is known
(Section S2.A, above, in the introduction to this protocol). As introduced earlier, two
potential events must be screened for: (1) site-specific on-target integration of the trans-
gene into the AAVS1 locus; (2) random integration of the targeting plasmid elsewhere
in the genome. It should be noted that while cells characterized only by the second type
of modification are very rare, as in most cases random integration of the plasmid will
not support expression of the gene trap–based puromycin resistance gene (see Section
2.A in the introduction to Basic Protocol 2), off-target integration events are observed
in 25% to 80% of correctly targeted lines (Bertero et al., 2016). Both on- and off-target
integration events can be efficiently and easily screened by PCR using genomic DNA as
template (Figure 5C.4.5B; Table 5C.4.3).
Site-specific transgene insertion is detected by using a primer pair in which one primer
is located on the transgene while the second maps to the genomic locus outside of the
homology arm (Figure 5C.4.6B). We recommend performing this type of PCR to confirm
that both the 5′- and 3′-end of the transgene have been correctly integrated. Thus, the
presence of the expected product in both of these “transgene integration” PCRs, which
we refer to as 5′-INT and 3′-INT PCR, indicates that at least one of the two alleles of the
AAVS1 locus has been targeted (Table 5C.4.3). Furthermore, performing another PCR
using the two primers mapping to the genomic locus outside of the homology arms allows
determining if only one or both of the two alleles have been edited (Figure 5C.4.6B).
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Table 5C.4.3 Inferring the Genotype of OPTiKD Clonal Lines from PCR Results































One or more band
absent or at incorrect
size
Any Any Incorrect targeting
No bands Band at expected
size
At least one band at
expected size
Untargeted
aOnly the most common results are described. Refer to Section S2.C (see introduction to Support Protocol 2) to interpret
other possible genotyping results.
bAlternatively the line could a mix of two of more clones with at least one wild-type allele.
cAlternatively the targeting plasmid is still present in the cells as an episome.
AAVS1 locus, insertion of the transgene leads to loss-of-allele PCR in which no product
is observed. This is not only because the transgene is very long, but also because the
CAG promoter contains an extremely GC-rich portion, which together result in PCR
amplification failure. Therefore, when no band is detected in this PCR, which we refer
to as locus PCR, homozygous targeting of the locus can be inferred (Table 5C.4.3).
The amplification of a PCR product can indicate: (1) a rare wild-type clone; (2) a
heterozygous clone; (3) a non-clonal population that contains a mixture of targeted and
untargeted alleles (see Section S2.B, above in the introduction to this protocol). While
the first option can be ruled out based on the result of 5′-INT and 3′-INT PCR, the
last two possibilities cannot easily be teased apart. Therefore, we recommend that only
clones showing homozygous targeting by locus PCR be selected for further analyses: not
only will this ensure higher expression of the inducible shRNA, but it also reinforces the
notion that the lines are most likely truly clonal.
Once on-target recombination of the transgene has been established, it is then advisable to
monitor possible off-target random integration. For this, we recommend a PCR reaction
using a primer specific to the transgene and a second primer located on the targeting
plasmid backbone outside of the homology arms (Figure 5C.4.6B). While this reaction
will readily reveal if any plasmid has been randomly integrated in the genome, it will
not result in amplification in case of on-target integration. In fact, during HDR, only the
homology arms will be incorporated in the AAVS1 locus, while the rest of the plasmid
backbone will be lost. Since random integration does not always involve the whole
plasmid, we recommend performing two such PCRs to monitor the 5′- and 3′-end of
the transgene cassette. The presence of a band in either of these two “backbone” PCRs,
which we refer to as 5′-BB and 3′-BB PCR, indicates that the targeting plasmid has likely
been stably integrated in a random genomic region. One possible exception to this is if the
plasmid is still found as an episome in the cells. However, if the genotyping is performed
according to the timeline suggested in the protocol below, this is an extremely unlikely
event. In fact, transiently transfected plasmids will be serially diluted following each cell
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episomal plasmid will be detectable by PCR 2 weeks post transfection. It is important to
mention that the PCRs described here will not detect random integration of the plasmid
if the transgene portion has been lost during such an event. However, as the primary goal
of this procedure is to identify OPTiKD lines with additional copies of the transgene
outside of the AAVS1 locus, this is not a significant limitation. Finally, it should be noted
that while 5′-BB and 3′-BB PCRs provide a rapid and sensitive method to detect random
integration of the transgene, the gold standard analysis for this would be to perform
Southern blotting with a DNA probe specific to the targeting vector. However, this is
a complex and time-consuming procedure that involves the use of radioactive reagents.
Thus, we suggest this only as a secondary screening and/or troubleshooting step.
Collectively, by performing the five PCR reactions described above, it is possible to de-
termine the most common genotypes found in clonal OPTiKD sublines (Table 5C.4.3).
In general, we recommend that only clones with homozygous integration of the targeting
plasmid and no off-target integration events be selected for further analysis in order to
ensure maximal reproducibility (see Section S2.A, above, in the introduction to this pro-
tocol). Since in our experience these lines are derived with an efficiency of approximately
25% (range: 10% to 40%; Bertero et al., 2016), screening of at least 12 clones is rec-
ommended (Figure 5C.4.6L). Nevertheless, homozygous clones containing extra copies
of the targeting plasmid can sometimes lead to a stronger level of inducible knockdown,
which might be advantageous when using sub-optimal shRNAs. In this case, we strongly
recommend validating the knockdown at the same stage of hPSC differentiation to be
examined experimentally, in order to ensure that the randomly integrated transgenes are
active in the cell type of interest (see Section S2.A, above, in the introduction to this
protocol).
Materials
OPTiKD colonies (Basic Protocol 3)
DNeasy Blood & Tissue Kit (Qiagen, cat. no. 69504)
LongAmp Taq DNA Polymerase (New England Biolabs, cat. no. M0323S)
10 mM dNTP mix (Promega, cat. no. U1511)
Locus_fw (custom oligonucleotide, see Table 5C.4.4)
Locus_rev (custom oligonucleotide, see Table 5C.4.4)
OPTtetR_fw (custom oligonucleotide, see Table 5C.4.4)
Puro_rev (custom oligonucleotide, see Table 5C.4.4)
Puro_rev2 (custom oligonucleotide, see Table 5C.4.4)
Backbone_fw (custom oligonucleotide, see Table 5C.4.4)
Backbone_rev (custom oligonucleotide, see Table 5C.4.4)
Dimethyl sulfoxide (DMSO), PCR-grade (Sigma Aldrich, cat. no. D9170)
1% (w/v) agarose gel in TBE containing 0.5 μg/ml ethidium bromide (see recipe;
use molecular biology grade agarose; ThermoFisher, cat. no. 10787018)
Recombinant human Laminin-521-coated 12-well culture plates (see recipe)
Permanent marking pen
8- or 12-channel pipettor appropriate for volumes between 2 and 7 µl
MicroAmp Optical 96-Well Reaction Plate (ThermoFisher, cat. no. N8010560)
MicroAmp Clear Adhesive Film (ThermoFisher, cat. no. 4306311)
Additional reagents and equipment for agarose gel electrophoresis and hPSC
culture (see Basic Protocols 2 and 3; Voytas, 2001; Costa, 2008)
S2.D: Preparatory steps
1. Obtain OPTiKD colonies according to Basic Protocol 3. After initiating drug selec-
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microscope and use a permanent pen to mark on the bottom of the plate the colonies
that are found in close proximity (less than 1 to 2 mm away). These will be excluded
from picking.
2. On the day before picking, pre-coat 12-well plates overnight with Laminin-521 as
described in Reagents and Solutions.
We recommend preparing at least one 12-well plate for each shRNA used to generate
OPTiKD hPSCs (see Section S2.C above, in the introduction to this protocol). Volumes
in this protocol are for plating picked colonies on 12-well plates. If another multi-well
format is preferable, scale these volumes according to the surface area.
3. When OPTiKD colonies are ready for picking (size of 500 to 1000 µm; step 14 of
Basic Protocol 3), use a permanent marking pen to mark those that have not been
previously excluded from picking (see step 1) and that show the expected hPSC
morphology with little or no background differentiation (Figure 5C.4.6J).
4. Remove the excess Laminin-521 coating solution from pre-coated 12-well plates
(see step 2) and immediately add 1 ml of complete E8 supplemented with 10 µM
Y-27632 and 1× penicillin-streptomycin. Transfer the plates to the incubator to
pre-equilibrate, and pre-warm Versene at 37°C in a heated water bath.
Addition of penicillin and streptomycin is optional but recommended if colonies will be
picked outside of the tissue culture hood, to minimize the risk of bacterial contamination.
S2.E: Picking
5. Aspirate the culture medium, rinse the cells once with 2 ml of DPBS without calcium
and magnesium, and incubate with 1 ml of Versene at 37°C in the incubator for up
to 2 min.
This gentle Versene pre-treatment step is critical to impair cell attachment to the extracel-
lular matrix. In colonies directly picked from Laminin-521-coated plates, the carryover of
extracellular matrix strongly inhibits attachment to the new plate. The timing of Versene
incubation is dependent on the cell line and on the size of the colonies. Proceed to the
next step as soon as the cells start to show early signs of disaggregation (see step 4 of
Basic Protocol 3): prolonged treatment can lead to the colonies lifting off prematurely.
6. Gently aspirate Versene and gently add 3 ml of DPBS without calcium or magnesium.
Cells are very prone to mechanical lifting at this stage, so proceed with extreme care.
7. Mechanically pick the pre-selected colonies (see step 3, above) by using a mi-
cropipettor equipped with a sterile tip. Use a microscope to facilitate visualization
during the procedure. Transfer each colony to a single well of a laminin-coated
12-well plate (step 2), then gently pipet up and down three to five times to triturate.
Before collecting the cells, aim to break up the colony into strips using the pipet tip to
facilitate its disaggregation (Figure 5C.4.6K). After plating the cells, confirm that small
clumps of 20 to 100 cells have been obtained, and if necessary triturate again by gently
pipetting three to five times. If the colonies are very large (750 to 1000 µm), it is possible
to split the cells into two wells and proceed directly to step 10. Alternatively, it is possible
to use some of the cell suspension directly for genotyping PCR. However, we discourage
this approach, since in our experience it can lead to a large number of false negative
results.
8. If any colony is left in the well used for picking, gently aspirate the DPBS and add
fresh complete E8 medium supplemented with 1× penicillin-streptomycin.
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9. On the next day, confirm that the picked colonies have attached, gently aspirate the
culture medium, and replace with fresh complete E8. Culture the cells according
to standard procedures until they are ready for passaging (see step 1 of Basic
Protocol 3).
S2.F: Genotyping
10. Split each clonal OPTiKD line into two wells of a laminin-coated 12-well plate:
one with approximately 1/3 of the cells and the second with the remaining 2/3.
Cells in the first well will be grown while the second will be used for genotyping.
Passage the cells according to steps 4 and 5 of Basic Protocol 3, above, but instead
of transferring the lifted cells into a conical tube, directly aliquot them into the new
wells.
11. After 24 to 48 hr, extract genomic DNA from the genotyping plate from the pre-
vious step using the DNeasy Blood & Tissue Kit according to the manufacturer’s
instructions. Dilute the DNA to 50 ng/µl.
Wait until the cells reach at least 30% confluence to ensure a sufficient yield. Samples
with concentration lower than 50 ng/µl can be used, but the concentration should never
be below 20 ng/µl to ensure a reliable result.
12. For each of the PCR reactions detailed in Table 5C.4.4 assemble a reaction master
mix to be used for all samples plus three recommended controls (volumes are for
one sample):
a. LongAmp Reaction Buffer (5×) 2 µl
b. dNTP mix (10 mM) 0.3 µl
c. Forward primer (5 µM in ddH2O), Table 5C.4.4 0.5 µl
c. Reverse primer (5 µM in ddH2O), Table 5C.4.4 0.5 µl
d. DMSO 0.2 µl
e. LongAmp Taq Polymerase 0.4 µl
f. Ultrapure ddH2O to 8 µl
13. Aliquot the reaction from step 12 into a 96-well plate (8 µl of per well) and add 2 µl
(100 ng) of genomic DNA for each sample in separate wells. Seal the plate with an
adhesive film.
We recommend also including the following controls: (1) wild-type hPSC DNA, 100 ng;
(2) targeting plasmid, 1 ng; (3) no template control (Figure 5C.4.6L and Table 5C.4.4).
14. Run the PCR in a thermocycler according to the following program (lid kept at
95°C):
a. 94°C 5 min
b. 94°C 15 sec
c. Annealing temperature (see Table 5C.4.4) 30 sec
d. 65°C Extension time (see Table 5C.4.4)
Repeat steps b to d for 34 cycles.
e. 65°C 3 min
f. 10°C hold
15. Remove the adhesive film from the plate and, using a multichannel pipettor, add
2 µl of gel loading dye. Mix by vortexing at low speed and run 6 µl of each reaction
on a gel for DNA electrophoresis as described in step 2 of Basic Protocol 2, using a
1.0% (w/v) agarose gel.
If possible we advise to use a multichannel pipettor to facilitate loading the gel.
16. Visualize the gel using a UV transilluminator to determine the results of each PCR
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OPTiKD line that was analyzed (Table 5C.4.3 and Section S2.C) and identify the
clones to be selected for further expansion and experimental analysis.
17. Confirm that the clones of interest have been growing well in the second 12-well
plate from step 10 of this protocol. Once they are ready to be passaged, split them
for expansion, banking, and experimental analyses (step 14 of Basic Protocol 3).
We recommend performing steps 11 to 16 within 24 to 48 hr in order to ensure that the
cells maintained on the second 12-well plate will not grow to overconfluence by the time
the genotypes have been determined.
BASIC
PROTOCOL 4
VALIDATION OF OPTIKD hPSCs
In this last section, we describe the validation of OPTiKD hPSCs. Given that this aspect
will vary broadly depending on the gene of interest, the reagents that are available to
study such gene, and the experimental question being investigated, a conventional step-
by-step protocol would be poorly suited to this task. Therefore, we instead present general
considerations in a discursive form to help the user design the most appropriate validation
experiments.
Materials
Tetracycline hydrochloride (Sigma-Aldrich, cat. no. T7660; see recipe for stock
solution)
4.A: Inducible knockdown using OPTiKD hPSCs
Knockdown can be induced by simple addition of the drug tetracycline the culture
medium at a recommended concentration of 1 µg/ml, a dose that does not induce toxicity
to hPSCs and does not interfere with hPSC differentiation. Note that the tetracycline
analog doxycycline is equally effective for inducing knockdown in hPSCs, but we have
not extensively tested potential side effects during hPSC differentiation. Tetracycline is
a light-sensitive reagent and should be protected from direct illumination during prepa-
ration, storage, and use. Aqueous solutions of tetracycline are unstable and gradually
become turbid due to hydrolysis and precipitation. Thus, aqueous tetracycline solutions
should be stored as single-use aliquots at –80°C (see Reagents and Solutions). Once
diluted in culture medium and maintained at 37°C, the half-life of tetracycline is ap-
proximately 24 hr. Therefore, we recommend performing medium changes at least every
other day. It is best to add fresh tetracycline to the culture medium just before use, but,
should it be preferable to prepare larger volumes of medium, these should be stored at
4°C and used within a week of preparation.
It is very important to keep in mind that tetracycline is a widely used antibiotic in livestock
animals such as cows and horses. Therefore, animal-derived products such as fetal bovine
serum (FBS) and bovine serum albumin (BSA) carry the risk of being contaminated with
tetracycline. It is therefore important to batch-test animal-derived reagents (in particular
FBS and derivatives) for absence of detectable tetracycline contamination before use
in OPTiKD hPSCs. Wherever possible, we recommend substituting such reagents with
tetracycline-free validated alternatives that are available from commercial suppliers.
4.B: Validation of OPTiKD hPSCs
We recommend validating newly generated OPTiKD hPSCs both at the transcript and
protein level. Importantly, if expression of the target gene is low or absent in hPSCs,
the cells should be first differentiated into an appropriate cell lineage expressing such
gene. This will usually be the cell type to be functionally analyzed in follow-up experi-
ments, but should differentiation into such lineage be expensive, laborious, and/or time
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type expressing similar levels of the gene. Transcript levels can be readily monitored by
quantitative real-time PCR (qPCR), which is our preferred validation method given its
simplicity, cost-effectiveness, and wide applicability to any gene of interest. When using
the Ct approach to quantify relative mRNA expression levels over control samples
(Livak & Schmittgen, 2001), it is important to validate that the expression of the chosen
housekeeping gene is not sensitive to the addition of tetracycline. Validation by qPCR
can be performed after 24 to 48 hr following induction of knockdown.
Once transcript-level knockdown has been confirmed, it is important to validate loss of
the protein product. This relies on the availability of a good antibody against the protein
of interest and is therefore not always possible. If such an antibody exists, we recommend
to initially validate OPTiKD cells by western blot, which allows for relatively simple and
rapid semi-quantitative evaluation of protein knockdown. Flow cytometry can provide an
alternative and more quantitative assessment with the added advantage that this is evalu-
ated at the single-cell level and thus interrogates the heterogeneity in the population. For
example, if a pseudo-clonal OPTiKD subline has been selected (Support Protocol 2), flow
cytometry can confirm that the knockdown is homogeneous and that the selected subline
is most likely clonal. If OPTiKD cells have not been clonally isolated, it is important
to ensure that the majority of the population (>90%) undergoes inducible knockdown
before proceeding with extensive follow-up experiments. Immunocytochemistry is an
alternative way to assess population heterogeneity in OPTiKD cells, while it also allows
for spatial and morphological analyses. However, immunocytochemistry is poorly quan-
titative and prone to false-positive signals, thus usually requiring extensive optimization.
Regardless of the technique used, wherever possible it is important that protein-level
validation be performed while including appropriate controls, one of the most important
being a cell type not expressing the protein of interest. This type of validation is better
performed after prolonged tetracycline treatment of at least 5 to 10 days in order to
ensure evaluation of the maximal level of protein knockdown that can be achieved (see
Commentary).
REAGENTS AND SOLUTIONS
Use deionized, distilled water (ddH2O) or equivalent in recipes and protocol steps.
Agarose gel (1%, 1.5%, or 4%) in TBE for DNA electrophoresis
Dissolve the required amount of agarose I powder [molecular biology grade (Ther-
moFisher, cat. no. 17850) or UltraPure Low Melting Point Agarose (ThermoFisher,
cat. no. 16520050) as called for in protocol] in 1×TBE buffer (see recipe) in a glass
bottle. Place a cap on the bottle but leave loose. Incubate at room temperature for 15
min to pre-dissolve. Microwave for about 1 to 2 min or until all of the powder is fully
dissolved, but do not let the solution boil. Allow the solution to cool at room tem-
perature for 5 to 10 min (the temperature of the solution should not go below 65°C
to prevent premature gelling) and add 10 mg/ml ethidium bromide (Sigma-Aldrich,
cat. no. E1510-10ML) to a final concentration of 0.5 µg/ml. After mixing, pour the
solution into a gel casting tray equipped with the appropriate combs and let the gel
set for 15 to 30 min before use.
Also see Voytas (2001).
Essential 8 (E8) medium, complete
Add 10 ml of provided 50× Essential 8 supplement to a 500-ml bottle of Essential
8 medium (ThermoFisher, A1517001) and mix by gently inverting (avoid making
bubbles, to prevent denaturation of the cytokines). Optionally, add 100× penicillin-
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complete Essential 8 medium at 4°C and use within 7 days to prevent loss of potency
of the associated cytokines.
Laminin-521-coated culture plates
Thaw Laminin-521 stock solution (BioLamina, cat.no. LN521-02) at 4°C overnight
and mix well by inversion before use. To prepare 1 ml of coating solution for final
coating at approximately 0.5 µg/cm2, add 50 µl of the stock to 950 µl of DPBS with
calcium and magnesium (ThermoFisher, cat. no. 14040133). Add 1 ml to one well
of 6-well plate (Corning, cat. no. 3516) or 0.5 ml to one well of a 12-well plate
(Corning, cat. no. 3513). Swirl to ensure that the bottom surface is entirely covered.
Tightly seal and incubate at 4°C overnight. Alternatively, plates can be coated for
2 hr at 37°C. Pre-coated plates can be stored at 4°C for up to 2 weeks provided they
do not dry out.
LB agar plates
Dissolve 20 g of agar powder (e.g., BD Difco) in 1 liter of LB broth and mix well.
Autoclave on liquid cycle and let cool until it is warm enough to touch (approximately
50°C). Add the appropriate antibiotic [ampicillin (Sigma-Aldrich, cat. no. A5354-
10ML)] to 100 µg/ml and swirl to mix (do not shake as this will create bubbles). Pour
into 10-cm petri dishes to completely cover the bottom surface. Allow the plates to
set for 2 hr at room temperature and store at 4°C up to 3 months.
Luria-Bertani (LB) broth
To prepare a 1 liter solution, mix:
1. 950 ml of ddH2O
2. 10 g tryptone (e.g., BD Difco)
3. 10 g NaCl
4. 5 g yeast extract (e.g., BD Difco)
Dissolve and adjust the pH to 7.0 with 5 N NaOH. Bring the volume to 1 liter with
ddH2O. Sterilize in the autoclave on a liquid cycle and store at room temperature for
up to 6 months. Let the medium cool to room temperature before use.
Tetracycline stock solution
Dissolve 50 mg of tetracycline hydrochloride in 5 ml of ultrapure ddH2O. The
resulting solution should have a mild yellow-orange color. Filter-sterilize using a
0.22-µm filter and prepare single-use 5- or 10-µl aliquots. Store at –80°C for up to
6 months.
Prepare this reagent protected from direct illumination.
Tris-borate-EDTA (TBE) buffer
To prepare a 1 liter 5× stock solution add:
1. 800 ml of ddH2O
2. 54 g of Tris base
3. 27.5 g of boric acid
4. 20 ml of 0.5 M EDTA (pH 8.0)
Mix by stirring until dissolved then bring volume to 1 liter with ultrapure ddH2O.
The pH should be approximately 8.3. Store at room temperature for up to 6 months.
To obtain a 1× working solution, add one volume of 5× TBE to four volumes of
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Y-27632 stock solution, 10 mM stock
To obtain a 10 mM solution dissolve 1 mg of Y-27632 powder (Tocris, cat. no. 1254)




Recent advances in our ability to perform
high-throughput analyses of genomes, tran-
scriptomes, and proteomes carry with them
the key challenge of functionally annotating
an ever-growing list of genes with potential
links to human development, physiology, and
disease (Cooper & Shendure, 2011). As a re-
sult, there is a high demand for simple, scal-
able, rapid and robust platforms for functional
genetic analyses in multiple human cell types,
including populations that are transitory dur-
ing development, rare, or inaccessible. Loss-
of-function experiments in hPSCs provide a
unique opportunity to address this major chal-
lenge, as they can differentiate into any adult
cell type of clinical interest (Trounson & De-
Witt, 2016). However, high-throughput func-
tional genetic applications of hPSCs require
easy and efficient methods to conditionally
manipulate gene expression in both hPSCs and
hPSC-derived cells. Indeed, this is necessary
both for the study of genes that are essential for
hPSC self-renewal and for functional analyses
at specific stages of differentiation.
Unfortunately, progress in this direction
was hampered for years due to the difficulty
in manipulating gene expression in hPSCs us-
ing most conventional methods (Cao et al.,
2010; Costa et al., 2007; Krishnan et al., 2006;
Ott et al., 2006; Stein et al., 2010; Yao et al.,
2004; Zwaka & Thomson, 2003). This situa-
tion dramatically changed following the recent
revolution in the field of genetic engineering
due to the development of customizable nu-
cleases such as ZFNs, TALENs, and, more
recently, CRISPR/Cas9 (Cong et al., 2013;
Jinek et al., 2012; Joung & Sander, 2013; Mali
et al., 2013; Urnov, Rebar, Holmes, Zhang,
& Gregory, 2010). These can be used to in-
duce site-specific double-strand DNA breaks
that are repaired either by the error-prone non-
homologous end joining (NHEJ) pathway, re-
sulting in random small insertions or deletions
(indels) that can generate loss-of-function al-
leles, or by HDR mechanisms driving recom-
bination of a donor DNA fragment carrying
specific mutations, thus resulting in precise
gene editing (Gaj et al., 2013; Kim & Kim,
2014). In particular, these methods can be ap-
plied to gene editing of human GSHs in order
to overexpress transgenes, genetic reporters,
and shRNAs (DeKelver et al., 2010; Gaj et al.,
2013; Hockemeyer et al., 2011; Hockemeyer
et al., 2009; Kun et al., 2014; Smith et al.,
2008).
These technological improvements have
recently provided the foundation of several
methods for conditional loss-of-function stud-
ies in hPSCs. However, these technologies still
have important drawbacks. First, even with
the advent of CRISPR/Cas9, recombination-
based inducible knockout is still quite complex
and time consuming, as it relies on generation
of gene-specific targeting vectors and on two
gene-targeting steps (Chen et al., 2015). Sec-
ondly, the iCRISPR inducible CRISPR/Cas9
knockout approach relies on the introduction
of random indels (González et al., 2014),
and thus generates a mixed cell population
carrying different mutations, including some
that do not induce loss of gene function.
Third, the CRISPRi-inducible CRISPR/Cas9
interference method relies on sgRNAs that
are either delivered by transient transfection,
which is poorly efficient and not fully repro-
ducible, or by random integration, which can
result in mosaic expression (Mandegar et al.,
2016). Moreover, all of the current inducible
CRISPR/Cas9-based methods involve condi-
tional overexpression of the Cas9 or of Cas9
fusion proteins by using an inducible promoter
(the tetracycline responsive element, or TRE)
that is heavily silenced during hPSC differen-
tiation into multiple lineages, even after target-
ing into GSHs (Bertero et al., 2016; Haenebal-
cke et al., 2013; Mandegar et al., 2016;
Ordovas et al., 2015). Therefore, these sys-
tems are unlikely to work in a diversity of cell
types.
On the contrary, the OPTiKD protocol de-
scribed here relies on a transgenic cassette
that has been extensively tested not to suf-
fer from silencing during hPSC differentia-
tion into a large number of cell types (Bert-
ero et al., 2016). Moreover, OPTiKD is easy
to implement (it relies on one straightforward
and scalable cloning step, and on subsequent
simple transfection of hPSCs), rapid (only one
gene targeting step is involved), efficient (more
than 95% efficiency in generating inducible
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efficiency the isolation of clonal lines can be
entirely bypassed). We also recently reported
a sister method to OPTiKD which we named
OPTiKO, for optimized inducible knockout
(Bertero et al., 2016). This approach takes
advantage of the same cassette used for in-
ducible shRNA expression in OPTiKD, but
repurposes it to drive an inducible sgRNA
for CRISPR/Cas9. By combining this with a
constitutively overexpressed Cas9 protein, we
were able to demonstrate tightly controlled
and efficient induction of gene knockout in
hPSCs and hPSC-derived cells (Bertero et al.,
2016; Fogarty et al., 2017). This method shares
many of the advantages of OPTiKD described
above, but the two approaches present distinct
features that make each most useful for cer-
tain applications. Indeed, full gene-knockout
with OPTiKO allows more powerful studies
of genes that are still functional even when ex-
pressed at low levels. Furthermore, OPTiKO
is also applicable to non-coding regulatory re-
gions of the genome, which represent a large
portion of disease-associated loci (Zhang &
Lupski, 2015). On the other hand, the ability
to tune the knockdown level using OPTiKD
permits studying genes whose complete loss
of function is lethal, while it also facilitates
the investigation of gene-dosage mechanisms.
Finally, OPTiKD is fully reversible.
Collectively, OPTiKD not only overcomes
the limitations of previous inducible shRNA
methods (Zafarana et al., 2009) but also pro-
vides an advantageous alternative to currently
available inducible knockout approaches for
the study of gene function in hPSCs and hPSC-
derived cells. Finally, while the current unit is
focused on the application of OPTiKD in hP-
SCs, we expect that this method will be widely
applicable with minor modifications to many
cell types that are amenable to genetic manip-
ulation, including adult stem cells and cancer




The most critical parameter to generate an
effective OPTiKD hPSC line is the identifica-
tion of a potent shRNA capable of inducing
strong gene knockdown. Wherever possible,
we recommend using pre-validated shRNAs
found in the literature or from the TRC library
(Section 1.A; see Basic Protocol 1 introduc-
tion). Choose shRNA with a validated knock-
down level of at least 75% (ideally >90%).
If no validated shRNAs are available for the
gene of interest, we recommend choosing the
shRNAs with the highest “Adjusted Score”
in the TRC library database. In the first in-
stance, we recommend the selection of at least
three validated shRNAs or six non-validated
shRNAs for the gene of interest: this should
result in having at least two good shRNAs
(>75% knockdown), which is the minimum
number of shRNAs that must be used in or-
der to validate the specificity of phenotypes
resulting from gene knockdown (see below).
In the event that this is not the case, more
shRNAs can be tested at a later stage. Should
this be possible, it is advised to pre-screen
non-validated shRNAs using alternative meth-
ods such as transient transfection into easy-to-
transfect cells, or lentiviral infection.
The second critical parameter in the pro-
cedure is the efficiency of hPSC gene target-
ing. For this, using hPSCs of the best possi-
ble quality is of the utmost importance. Cells
should be growing well in feeder-free condi-
tions, have little or no background differen-
tiation, and be amenable to near single-cell
growth. For this, we recommend using Es-
sential 8 medium and Laminin-521 coating,
as they have proven widely applicable to a
number of hPSCs that are hard to maintain
in other feeder-free culture conditions. Aside
from this, effective plasmid delivery is crucial,
and transfection efficiency ought to be at least
20% to increase the chances of experimental
success. Should a specific hPSC demonstrate
reluctance to transfect even after extensive
optimization, nucleofection can be a valid al-
ternative.
Selected troubleshooting procedures are
described in the protocols, and a comprehen-
sive reference can be found in Table 5C.4.5.
Anticipated Results
OPTiKD hPSCs allow tightly controlled,
potent, homogeneous, dose-responsive, and
reversible inducible gene knockdown both in
hPSCs and in hPSC-derived lineages (Fig-
ure 5C.4.7A-F). When a potent shRNA has
been selected, this is expected to show a 75%
to 95% reduction in both mRNA and protein
levels (Figure 5C.4.7F). Furthermore, when
compared to wild-type controls or OPTiKD
cells expressing an shRNA targeting a differ-
ent transcript (see below), mRNA levels in
OPTiKD cells maintained in the absence of
tetracycline should not be significantly differ-
ent thanks to the robust transcriptional repres-
sion of the shRNA [Section 2.A (see introduc-
tion to Basic Protocol 2); Figure 5C.4.7A and
5C.4.7F]. We recommend culturing cells in
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Table 5C.4.5 Troubleshooting
Problem Possible causes Troubleshooting Possible solutions




vector (step 9 of
Basic Protocol 2 or








check design (step 7








annealing (step 5 of
Basic Protocol 2)
Re-attempt annealing but
increasing the incubations at
80, 75, and 70°C to 10 min
and/or increasing the ionic
strength of the annealing











Perform ligation overnight at
room temperature and/or use
new ligase enzyme (step 7 of
Basic Protocol 2 or step 3 of






















(step 7 of Basic
Protocol 2)
Re-prepare vector increasing
incubation time and/or using
















DMSO up to 5%; increase
template concentration; use a









- Screen additional bacterial
clones and/or repeat cloning
using PAGE-purified
oligonucleotides












provided with the kit
Re-assemble the vector
increasing the incubation
time at 50°C to 4 hr (step 8 of
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Table 5C.4.5 Troubleshooting, continued
Problem Possible causes Troubleshooting Possible solutions













stocks; re-prepare the shRNA









- Screen additional clones.
Repeat PCR reducing the
number of cycles to 25-30
(step 5 of Support Protocol
1). Use new enzyme.
















cytometry after 24 hr
Optimize transfection for
specific hPSC line by varying
plasmid amount (1-4 µg),
GeneJuice to plasmid ratio
(2-6 µg/µl), cell number
(100,000-500,000), and
timing (during plating or after








- Use minimal concentration
required to kill wild-type
hPSCs (step 12 of Basic
Protocol 3). Decrease
puromycin dose by half after
48 hr of selection. Add
ROCK inhibitor for up to
72 hr during selection.
Remove puromycin once








plasmids (step 9 of
Basic Protocol 3)
Re-prepare the ZFN plasmids
and confirm their identity by
restriction digestion and
sequencing. If other
nucleases have been used
switch to the plasmids
recommended in the protocol.
Differentiation of
hPSCs










- Prepare fresh complete
Essential 8 medium daily. If
other culture conditions have
been used switch to Essential
8 and Laminin-521 as







Supplement 44 Current Protocols in Stem Cell Biology
Table 5C.4.5 Troubleshooting, continued
Problem Possible causes Troubleshooting Possible solutions











- Use minimal concentration
required for complete killing
of wild-type hPSCs within
48 hr (step 12 of Basic
Protocol 3). Start puromycin
selection earlier










single cells in 96- or
384-well plates
Repeat targeting procedure
and closely monitor resulting
colonies daily (steps 1-3 of
Support Protocol 2). Reduce
the number of transfected
cells (scale other reagents
accordingly). Seed cells on
larger plate format (scale




- Optimize transfection for
specific hPSC line as
described in point 8 of this
table
















Troubleshooting points 8 to
10. Include the recommended











QC plasmid used for










Design a new shRNA and/or
find a validated shRNA.
Generate vector containing
multiple shRNAs against the






















Grow cell in presence of
puromycin even after
selection is completed. Thaw
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Table 5C.4.5 Troubleshooting, continued






























Lower the concertation of
tetracycline to sub-toxic


























Focus only on more potent
shRNAs (>75% knockdown)









Exclude non specific shRNAs










maximal induction of gene knockdown, but if
preferable this dose could be lowered down
by a factor of 10 without seeing a substantial
decrease in efficiency (Figure 5C.4.7C). Nev-
ertheless, doses between 10 and 100 ng/ml will
lead to dose-dependent effects on the induction
of gene knockdown (Figure 5C.4.7C), which
can be advantageous in certain experimental
settings. Less than 10 ng/ml tetracycline shows
no detectable activity.
Induction of knockdown at the transcript
level is extremely rapid and has proven con-
sistent across the multiple genes we have
tested, regardless of the cell type, with
near-maximal decrease observed between 12
and 24 hr after addition of tetracycline
(Figure 5C.4.7D). In fact, shRNAs induce
active degradation of their target transcripts
through the micro-RNA machinery, a process
which is largely transcript-independent (Lam-
beth & Smith, 2013). On the contrary, protein
loss is only consequential to reduced trans-
lation upon mRNA knockdown and is thus
largely dependent on the steady-state level
and the half-life of the protein, as well as on
the cell type. We have observed near-maximal
protein loss in OPTiKD hPSCs anywhere be-
tween 2 to 5 days after addition of tetracycline.
However, hPSCs are rapidly dividing cells
that, upon mRNA knockdown, will serially di-
lute the protein following each cell division.
On the other hand, when knockdown is in-
duced in cells that do not proliferate as rapidly
as hPSCs, maximal knockdown of very stable
proteins such as EGFP (whose half life is more
than 24 hr) can require up to 4 weeks (Bert-
ero et al., 2016). Therefore, if the timing of




































































































































































































































Figure 5C.4.7 Performance of OPTiKD in hPSCs and hPSC-derived cells. Data presented in this figure has been
previously presented in Bertero et al. (2016) and selectively reproduced here to provide representative examples
of the expected results when using OPTiKD. (A) Quantification of EGFP median fluorescence intensity (MFI) in
EGFP OPTiKD hESCs (clonal sublines). Homozygous ROSA26 CAG-EGFP hESCs (R26 EGFP; constitutive EGFP
expression) were re-targeted with pAAV-Puro_siKD-EGFP (homozygous targeting). Cells were analyzed in absence
(–) or presence (+) of tetracycline (TET) for 5 days. EGFP levels were compared to those in homozygous ROSA26
CAG-EGFP hESCs. Results are from two to three individual lines per condition. (B) Representative flow cytometry
EGFP quantification in EGFP OPTiKD hESCs treated as described in panel A. (C) Tetracycline dose-response curve
for EGFP knockdown in EGFP OPTiKD hESCs. The half-maximal inhibitory concentration (IC50) is reported. Results
are from two independent cultures per dose, and the mean is shown. (D) EGFP mRNA knockdown and rescue kinetics
in EGFP OPTiKD hESCs. Results are from two independent cultures per time point. (E) EGFP mRNA expression
measured by quantitative real-time PCR (qPCR) in absence (CTR) or presence of tetracycline for 5 days (TET) in the
indicated cell types derived from EGFP OPTiKD hESCs. EGFP levels are reported relative to control conditions for
each individual lineage. Pluri: undifferentiated hESCs; Neuro: neuroectoderm; Meso: lateral plate mesoderm; Endo:
definitive endoderm; NC: neural crest; Osteo: osteocytes; Chondro: chondrocytes; SMC: smooth muscle cells; Epi:
epicardium; Fibro: cardiac fibroblasts; Intestine: intestinal organoids; Panc: pancreatic cells; Chol: cholangiocytes;
Hep: hepatocytes. (F) Representative qPCR validation of OCT4 and B2M OPTiKD hESCs (clonal sublines). Cells
were analyzed in the absence (CTR) or presence of tetracycline for 5 days (TET). Clones were analyzed in duplicate.
design, this aspect must be verified for each
gene of interest and in the specific cell type to
be studied.
Withdrawal of tetracycline from knock-
down OPTiKD cells allows rescue of the
knockdown (Figure 5C.4.7D). For this, it is im-
portant to extensively wash the cells with fresh
medium in order to remove all traces of tetra-
cycline from the culture (two washes of 5 min
each should suffice). Rescue of mRNA expres-
sion follows a slower kinetics compared to the
induction of knockdown, since the shRNA per-
sists for 2 to 3 days even after removal of tetra-
cycline. In our experience, it takes between 5
and 7 days to see near-maximal recovery in
gene expression in hPSCs. In this, the tim-
ing varies from gene to gene depending on
the transcriptional activity, the half-life of the
mRNA, and the steady-state level that must be
reached to attain the expression observed prior
to the induction of knockdown. Rescue of pro-
tein expression follows a similar kinetics but is
delayed by 1 to 3 days, depending on the trans-
lation rate and protein stability. Nevertheless,
although these general guidelines can provide
a rule of thumb applicable to most genes, this
aspect will need to be determined in detail for
every gene of interest if the precise timing is
key to the experimental design.
Experiments for functional analyses using
OPTiKD hPSCs must be designed to include
a number of controls that allow robust eval-
uation of phenotypic consequences of gene
knockdown. Most importantly, each knock-
down sample ought to be paired with cells
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tetracycline. This is the essential control to be
used when measuring any potential change in
cell behavior following knockdown, as it pro-
vides the closest biological comparison. Aside
from this basic control, we also recommend in-
cluding OPTiKD cells that express an shRNA
targeting a different gene that is known not to
be involved in the biological process of interest
(unrelated shRNA control), or an shRNA that
does not target any known human gene (scram-
bled shRNA control). These cells should be
examined both in the absence of tetracycline
and after addition of tetracycline. The first as-
pect allows an evaluation of line-to-line vari-
ability across OPTiKD cells, which is partic-
ularly important if a clonal OPTiKD subline
is being used (Section S2.A; see Support Pro-
tocol 2 introduction). It also functions as con-
trol for any potential biological effects induced
by the gene targeting procedure. Unrelated or
scrambled shRNA controls treated with tetra-
cycline are key to: (1) excluding that tetracy-
cline has any side effects in the biological pro-
cess of interest, as this drug can have metabolic
effects in certain cell types (Chatzispyrou,
Held, Mouchiroud, Auwerx, & Houtkooper,
2015; Moullan et al., 2015); (2) exclude non-
specific effects due to cellular overespres-
sion of shRNAs, which can, under certain
conditions, compete with the endogenous
miRNA processing pathways (Boudreau, Mar-
tins, & Davidson, 2009; Grimm et al., 2006).
Of note, if multiple shRNAs are being ex-
pressed from the same OPTiKD vector (Sup-
port Protocol 1), we recommend that the unre-
lated or scrambled shRNA control also include
an equal number of shRNAs in order to more
closely mimic the level of shRNA overexpres-
sion induced under these conditions. Having
clarified the importance of these additional
controls, we would like to stress that our ex-
perience has revealed no obvious side effects
of OPTiKD in the specification of any of the
many hPSC-derived cell types we tested due
to the gene targeting procedure, the treatment
with tetracycline, or the overexpression of up
to three shRNAs (Bertero et al., 2016). While
we recommend including all these controls
when a new cell type and/or biological process
are being investigated for the first time, once
nonspecific effects inherent in the method have
been excluded, it is possible to include only
the no-tetracycline control in order to simplify
experimental procedures and analyses.
While shRNAs are a versatile, powerful,
and easy-to-implement tool, as with any ex-
perimental technique there are some inherent
limitations that need to be considered when in-
terpreting the results. It is well established that
certain shRNAs can have profound nonspecific
effects by leading to down-regulation of un-
related transcripts that share partial sequence
homology (Jackson et al., 2003). While over
the years computational tools used to design
shRNAs have been greatly improved to min-
imize such potential off-target effects (Pei &
Tuschl, 2006), they are by no means perfect.
Therefore, appropriate controls must be put in
place to ensure that any observed effects fol-
lowing shRNA overexpression are truly spe-
cific to the knockdown of the gene of inter-
est (Cullen, 2006). While the gold standard
for this is to rescue the phenotype by over-
expressing an shRNA-resistant transcript, this
is technically quite challenging and time con-
suming, and therefore might not be widely ap-
plicable. Furthermore, interpretation of rescue
experiments is not always straightforward, as
the gene overexpression often exceeds physi-
ological expression levels and thus can lead to
yet other potential confounding effects. There-
fore, as a more rapid and practical alternative,
we recommend that at least two shRNAs, but
ideally three or four, should be used in order
to validate that the phenotype is consistently
reproduced with multiple shRNAs. Should
this not be feasible in a first instance, for
example in a case where multiple genes are
being screened at the same time, we recom-
mend that any positive hit should be further
validated with new independent shRNAs. Fi-
nally, cross-validation of the results using an
independent method is also good practice.
A final aspect worth discussing is that, as
with any experiment, it is important that suf-
ficient biological and technical replication be
performed to ensure the statistical significance
of the results. This must follow established
conventions set by the scientific community,
and where appropriate should be determined
according to power calculations to predeter-
mine the amount of replication required to
reliably determine an effect of a given mag-
nitude given the expected degree of biolog-
ical variability (Nakagawa & Cuthill, 2007;
Vaux, Fidler, & Cumming, 2012). Specifi-
cally to OPTiKD, we recommend that multi-
ple independently-derived hPSC lines should
be used as biological replicates, in partic-
ular if clonal sub-lines have been isolated
(Section S2.A; see Support Protocol 2 intro-
duction). Furthermore, experiments should be
performed in hPSCs or hPSC-derived cells at
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Time Considerations
Figure 5C.4.2 outlines the experimental
procedure and the timelines associated with
each of the protocols described in this unit.
Collectively, an experienced user can com-
plete the four basic protocols and generate
OPTiKD hPSCs in as little as 3 weeks, while
we estimate that a first-time user should allow
up to 6 weeks. Inclusion of support protocols
to assemble targeting vectors for multiple in-
ducible knockdowns and/or to clonally isolate
OPTiKD hPSCs will add approximately 2 to 3
weeks to the process.
The procedure can be stopped at the end of
each protocol. Additionally, molecular cloning
experiments described in Basic Protocol 2, the
Alternate Protocol, and Support Protocol 1 are
largely flexible: intermediate DNA products
can be stored at 4°C overnight or at –20°C for
up to 1 month, and bacteria can be stored at
4°C as liquid culture or LB agar plates for up
to 1 week, or at –80°C as glycerol stocks for
long-term storage. The gene targeting proce-
dures are less flexible, and it is recommended
to allow 1 to 2 weeks of consecutive work to
complete Basic Protocol 3. If clonal isolation
of OPTiKD lines is desirable, it is recom-
mended to allow 2 to 4 consecutive weeks
to complete both Basic Protocol 3 and Sup-
port Protocol 2. Nevertheless, if necessary, it
is possible to freeze non-clonal OPTiKD hP-
SCs at the end of Basic Protocol 3 and then
initiate Support Protocol 2 at a later stage by
seeding individual cells into 96- or 384-well
plates for clonal isolation. Finally, if OPTiKD
cells are to be analyzed following hPSC dif-
ferentiation, the timing required for generation
of the cell type of interest must be taken into
account, and this can vary from a week up to
several months.
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González, F., Zhu, Z., Shi, Z.-D., Lelli, K., Verma,
N., Li, Q. V., & Huangfu, D. (2014). An
iCRISPR Platform for rapid, multiplexable, and
inducible genome editing in human pluripotent
stem cells. Cell Stem Cell, 15, 215–226. doi:
10.1016/j.stem.2014.05.018.
Gray, D. C., Hoeflich, K. P., Peng, L., Gu, Z., Gogi-
neni, A., Murray, L. J., . . . Davis, D. P. (2007).
pHUSH: A single vector system for conditional
gene expression. BMC Biotechnology, 7, 61. doi:
10.1186/1472-6750-7-61.
Grimm, D., Streetz, K. L., Jopling, C. L., Storm,
T. A., Pandey, K., Davis, C. R., . . . Kay, M.
A. (2006). Fatality in mice due to oversaturation
of cellular microRNA/short hairpin RNA path-
ways. Nature, 441, 537–541. doi: 10.1038/na-
ture04791.
Haenebalcke, L., Goossens, S., Naessens, M.,
Kruse, N., Farhang Ghahremani, M., Bar-
tunkova, S., . . . Haigh, J. J., (2013). Efficient
ROSA26-based conditional and/or inducible
transgenesis using RMCE-compatible F1 hy-
brid mouse embryonic stem cells. Stem Cell
Reviews, 9, 774–785. doi: 10.1007/s12015-013-
9458-z.
Henriksen, J. R., Løkke, C., Hammerø, M.,
Geerts, D., Versteeg, R., Flaegstad, T., & Ein-
vik, C. (2007). Comparison of RNAi effi-
ciency mediated by tetracycline-responsive H1
and U6 promoter variants in mammalian cell
lines. Nucleic Acids Research, 35, e67. doi:
10.1093/nar/gkm193.
Herbst, F., Ball, C. R., Tuorto, F., Nowrouzi,
A., Wang, W., Zavidij, O., . . . Glimm, H.
(2012). Extensive methylation of promoter
sequences silences lentiviral transgene ex-
pression during stem cell differentiation in
vivo. Molecular Therapy, 20, 1014–1021. doi:
10.1038/mt.2012.46.
Hockemeyer, D., Soldner, F., Beard, C., Gao, Q.,
Mitalipova, M., DeKelver, R. C., . . . Jaenisch,
R. (2009). Efficient targeting of expressed
and silent genes in human ESCs and iPSCs
using zinc-finger nucleases. Nature Biotechnol-
ogy, 27, 851–857. doi: 10.1038/nbt.1562.
Hockemeyer, D., Wang, H., Kiani, S., Lai, C. S.,
Gao, Q., Cassady, J. P., . . . Jaenisch, R. (2011).
Genetic engineering of human pluripotent cells
using TALE nucleases. Nature Biotechnology,
29, 731–734. doi: 10.1038/nbt.1927.
Jackson, A. L., Bartz, S. R., Schelter, J., Kobayashi,
S. V., Burchard, J., Mao, M., . . . Linsley, P. S.
(2003). Expression profiling reveals off-target
gene regulation by RNAi. Nature Biotechnol-
ogy, 21, 635–637. doi: 10.1038/nbt831.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M.,
Doudna, J. A., & Charpentier, E. (2012). A pro-
grammable dual-RNA-guided DNA endonucle-
ase in adaptive bacterial immunity. Science, 337,
816–821. doi: 10.1126/science.1225829.
Joung, J. K., & Sander, J. D. (2013). TALENs:
A widely applicable technology for targeted
genome editing. Nature Reviews, Molecular
Cell Biology, 14, 49–55. doi: 10.1038/nrm3486.
Kappel, S., Matthess, Y., Kaufmann, M., &
Strebhardt, K. (2007). Silencing of mam-






Supplement 44 Current Protocols in Stem Cell Biology
expression. Nature Protocols, 2, 3257–3269.
doi: 10.1038/nprot.2007.458.
Kim, H., & Kim, J. S. (2014). A guide to
genome engineering with programmable nucle-
ases. Nature Reviews, Genetics, 15, 321–334.
doi: 10.1038/nrg3686.
Krishnan, M., Park, J. M., Cao, F., Wang, D.,
Paulmurugan, R., Tseng, J. R., . . . Wu, J. C.
(2006). Effects of epigenetic modulation on re-
porter gene expression: Implications for stem
cell imaging. FEBS Journal, 20, 106–108. doi:
10.1096/fj.05-4551fje.
Kun, Q., Tzu-Ling, H., Hong, C., Lisle, W. B., Yue-
jun, C., Jingyuan, C., . . . Su-Chun, Z. (2014).
A simple and efficient system for regulating
gene expression in human pluripotent stem cells
and derivatives. Stem Cells, 32, 1230–1238. doi:
10.1002/stem.1653.
Lambeth, L. S., & Smith, C. A. (2013). Short
hairpin RNA-mediated gene silencing. Meth-
ods in Molecular Biology, 942, 205–232. doi:
10.1007/978-1-62703-119-6_12.
Laperle, A., Hsiao, C., Lampe, M., Mortier, J., Saha,
K., Palecek, S. P., & Masters, K. S. (2015). α-5
laminin synthesized by human pluripotent stem
cells promotes self-renewal. Stem Cell Reports,
5, 195–206. doi: 10.1016/j.stemcr.2015.06.009.
Lian, X., Hsiao, C., Wilson, G., Zhu, K., Hazeltine,
L. B., Azarin, S. M., . . . Palecek, S. P. (2012).
Robust cardiomyocyte differentiation from hu-
man pluripotent stem cells via temporal modu-
lation of canonical Wnt signaling. PNAS, 109,
E1848–57. doi: 10.1073/pnas.1200250109.
Livak, K. J., & Schmittgen, T. D. (2001). Anal-
ysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta
Delta C(T)) method. Methods, 25, 402–408. doi:
10.1006/meth.2001.1262.
Lu, H. F., Chai, C., Lim, T. C., Leong, M. F., Lim,
J. K., Gao, S., . . . Wan, A. C. A. (2014). A
defined xeno-free and feeder-free culture system
for the derivation, expansion and direct differen-
tiation of transgene-free patient-specific induced
pluripotent stem cells. Biomaterials, 35, 2816–
2826. doi: 10.1016/j.biomaterials.2013.12.050.
Luo, C., Lü, D., Pan, J., & Long, M. (2016). Im-
proving the gene transfection in human embry-
onic stem cells: Balancing with cytotoxicity and
pluripotent maintenance. ACS Applied Materi-
als & Interfaces, 8, 8367–8375. doi: 10.1021/ac-
sami.6b00353.
Ma, H., Wu, Y., Dang, Y., Choi, J.-G., Zhang,
J., & Wu, H. (2014). Pol III promoters to
express small RNAs: delineation of transcrip-
tion initiation. Molecular Therapy, 3, e161. doi:
10.1038/mtna.2014.12.
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell,
M., DiCarlo, J. E., . . . Church, G. M. (2013).
RNA-guided human genome engineering via
Cas9. Science, 339, 823–826. doi: 10.1126/sci-
ence.1232033.
Mandal, P. K., Ferreira, L. M. R., Collins, R., Meiss-
ner, T. B., Boutwell, C. L., Friesen, M., . . .
Cowan, C. A. (2014). Efficient ablation of genes
in human hematopoietic stem and effector cells
using CRISPR/Cas9. Cell Stem Cell, 15, 643–
652. doi: 10.1016/j.stem.2014.10.004.
Mandegar, M. A., Huebsch, N., Frolov, E. B., Shin,
E., Truong, A., Olvera, M. P., . . . Conklin, B.
R. (2016). CRISPR interference efficiently in-
duces specific and reversible gene silencing in
human iPSCs. Cell Stem Cell, 18, 541–553. doi:
10.1016/j.stem.2016.01.022.
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